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Abstract
Stomatin-like Protein 2 (SLP-2) has been identified as a stress-inducible transcript and 
has been shown to interact with and stabilize mitochondrial proteins.  Since mitochondria 
are critical for neuronal function, we hypothesized that SLP-2 regulates neuron survival 
in response to stressful stimuli.  A conditional SLP-2 knockout mouse (deletion) and the 
SN56 cell line (upregulation) were employed to study the role of SLP-2 in mitochondrial 
dynamics and neuron survival.  SLP-2 deficient primary cortical neurons displayed 
significantly decreased levels of various mitochondrial respiratory chain proteins, 
indicating SLP-2 contributes to maintenance of mitochondrial membrane integrity.  
SLP-2 was up-regulated in response to oxidative stress and DNA damage, but was not 
required for stress-induced mitochondrial biogenesis.  The level of SLP-2 expression had 
a significantly different effect on neuron survival, depending on the target of the insult.  
The results of this study improve our understanding of the role of SLP-2 in mitochondrial 
stress responses, bioenergetics, and survival in neurons.
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Chapter 1: Introduction
1.1   Mitochondria and Neuronal Activity
The central nervous system (CNS) uses approximately twenty percent of the oxygen 
consumed at rest (Gutowicz, 2011; Kann & Kovacs, 2007).  Neurons are highly 
metabolic, differentiated cells that require large amounts of adenosine triphosphate 
(ATP), in order to carry out their various functions.  As a result, they rely heavily on 
proper mitochondrial function for a number of fundamental neuronal processes such as 
energy production, synaptogenesis, calcium buffering, axonal and dendritic transport, and 
synaptic transmission (Knott et al., 2008; Kann & Kovacs, 2006). 
Although it has a large oxidative capacity, the brain has limited ability to withstand 
oxidative stress.  The majority of ATP in neurons is generated by the mitochondria 
through oxidative phosphorylation (OXPHOS).  As a result, neurons have a tremendous 
dependence on mitochondrial OXPHOS and a particular vulnerability to mitochondrial 
dysfunction.  Furthermore, neurons are functionally and morphologically heterogeneic 
between cell type and brain region.  As a result, there is a difference in metabolic 
requirement between neuronal cell type, as well as the axonal and presynaptic regions of 
each individual neuron, which necessitates differential regulation of energy production 
(Kann & Kovacs, 2006; Calabrese et al., 2001).
Neuronal activity is associated with transient elevations in calcium, a second messenger 
important for neural plasticity that can also, in excessive amounts, lead to cell 
excitotoxicity.  Mitochondria play an important role in buffering cellular calcium levels, 
especially at the level of the synapse, in order to maintain proper neuronal function.  
Additionally, synaptic transmission requires maintenance of plasma membrane potential, 
release and reuptake of neurotransmitters, and in the case of high frequency or prolonged 
firing, build up of a reserve pool of neurotransmitter-containing vesicles as well as 
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localized protein translation.  All of these processes are extremely energy demanding and 
require an adequate number of mitochondria at the synapse (Kann & Kovacs, 2006; 
Billups & Forsythe, 2002; Vos et al., 2010).
Due to their ability to undergo fission and fusion, migrate through cells, and coordinate 
regulated turnover, mitochondria are able to adapt to changes in cellular requirements 
depending on physiological cues or environmental stimuli (Chen & Chan, 2006, 2009).  
Cooperation of mitochondrial fission and fusion with mitochondrial transport is 
important, especially in neurons with long axons, to ensure that the proper number of 
mitochondria arrive at the synapses.  Furthermore, proper mitochondrial dynamics are 
critical in neurons as they allow mitochondria to interact and communicate with each 
other.  This in turn facilitates mitochondrial movement and distribution, over long 
distances, to synapses and areas of high metabolic activity, where they are needed the 
most.  Synaptogenesis, which includes dendritic spine morphogenesis, requires 
localization of mitochondria into dendritic sites of development and plasticity.  
Mitochondrial proteins Drp1 (dynamin-related protein 1) and OPA1 (optic atrophy 1), 
which are involved in fission and fusion respectively, are essential in preserving the level 
of mitochondrial content necessary for spine formation, further illustrating the 
importance of proper mitochondrial dynamics and movement (Li, 2004; Lu, 2009; Chen 
& Chan, 2006, 2009).
Figure 1 provides a schematic describing the mechanisms by which mitochondrial 
dysfunction can result in improper mitochondrial organization within neurons, and 
thereby contribute to neuronal dysfunction.  The importance of the interaction between 
mitochondrial dynamics, energy metabolism and neuronal function is supported by the 
level of cellular dysfunction that ensues when mitochondrial dynamics are disrupted.  
Mitochondrial defects appear to have an indisputable role in neuronal deficiency, given 
that oxidative stress, alterations in apoptosis and impairment of electron transport chain 
(ETC) complexes have all been shown to contribute to neurodegenerative disease 
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progression (Lu, 2009; Chen & Chan 2006, 2009; Santos & Cardoso, 2012; Calabrese et 
al., 2001).   
Alzheimer’s disease (AD) is the most common age-related neurodegenerative disorder 
and is marked by cognitive impairment due to progressive neuronal cell loss due to the 
accumulation of amyloid-β (Aβ) plaques and neurofibrillary hyperphosphorylated tau 
protein tangles (NFT) (de Moura et al., 2010).  Impaired mitochondrial function in this 
diseased state triggers Aβ deposition, synaptic dysfunction and degeneration, and 
generation of NFT.  Experimental studies have shown an over-expression of Aβ protein 
resulting in decreased expression of fission proteins Drp1 and Fis1 and fusion protein 
OPA1 (Section 1.2.1).  The altered expression of these mitochondrial proteins in AD is 
associated with mitochondrial dysfunction and fragmentation, depolarization of the 
mitochondrial membrane, and a resultant increase in reactive oxygen species (ROS) and 
ATP production thereby contributing to a cycle of increased ROS production (Section 
1.4.2) (Wang et al., 2008).
Parkinson’s disease (PD), the second most prevalent neurodegenerative disorder 
following AD, is characterized by extensive and progressive loss of dopaminergic 
neurons in the substantia nigra pars compacta as well as an accumulation of intraneuronal 
inclusions, known as Lewy bodies, in the remaining neurons.  Several studies have linked 
PD with mitochondrial function and oxidative stress.  The most common alterations 
detected in patients with PD are complex I deficiency, dysfunction and decreased activity 
of Complexes I and IV, and an increase in oxidative damage (Sections 1.4.1, 1.4.2) 
(Moran et al. 2012; Zhu & Chu, 2010; Xie et al., 2010; Henchcliffe & Beal, 2008; 
Muftuoglu et al., 2004; Palacino et al., 2004; Poole et al., 2008).  Complex I inhibitors 
including 1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine (MPTP), 1-methyl-4-
phenylperidinium (MPP+), and rotenone, can elicit PD-like symptoms in both humans 
(MPTP) and animal models (MPP+, rotenone) (Jones & Miller, 2008; Perier et al., 2005; 
George et al., 2010; Cicchetti et al., 2005).
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Huntington’s disease (HD) is a progressive neurodegenerative disorder that differs from 
AD and PD in that it is solely caused by a genetic abnormality.  Due to an abnormal CAG 
trinucleotide repeat in the N-terminal region, a conformational change results in the 
huntingtin protein and leads to a number of neurological defects (Imarisio et al., 2008).  
Mitochondrial dysfunction, involving reduced ETC activity at complexes II, III and IV 
(Section 1.4.1), has been strongly linked to HD (Benchoua et al., 2006; Gu et al., 1996).  
Irreversibly inhibiting complex II with 3-nitropropionic acid (3-NP) results in increased 
ROS production and damage to mitochondrial but not nuclear DNA in both cellular and 
animal models, with additional neurodegeneration observed in rats and nonhuman 
primates (Mandavilli et al., 2005; Brouillet et al., 2005; Acevedo-Torres et al., 2009; 
Damiano et al., 2010).
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Figure 1. Mechanisms of neuro al dysfunctio . In healthy eurons (a) mitochondria 
(green) are actively distributed over long distances from the cell body to dendritic and 
axonal termini where they are required for the production of ATP and calcium 
homeostasis.  Reduced mitochondrial fusion (b) results in fragmented, dysfunctional 
mitochondria (red) with structural defects.  Subsequently, a lack of fusion results in 
defective transport  capacity and prevents proper distribution of mitochondria to areas 
distant from the soma. Reduced mitochondrial fission (c) results in mitochondrial 
lengthening and formation of a highly interconnected network.  A portion of these 
mitochondria are also defective (red), and poorly distributed, due to their aggregation 
near the soma.  Mitochondria that are defective primarily  in transport capacity (d) result 
similarly  in unequal distribution of mitochondria to peripheral axons and dendrites.  This 
figure is adapted from Chen and Chan, 2009.
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1.2   Mitochondrial Dynamics
Mitochondria, the double membrane bound powerhouses of eukaryotic cells, are highly 
metabolic organelles that serve a critical bioenergetic role in many cellular functions.  In 
addition, these tubular-shaped structures are central to a number of cell regulatory and 
signaling processes by way of response to an assortment of physiological and genetic 
stresses, communications from other organelles, and signaling in cell proliferative and 
death pathways.  As a convergence point for a number of signaling pathways, 
mitochondria appear to play an important role in receiving, coordinating, and transmitting 
cellular signals, by altering their own shape and dynamic response. Mitochondrial 
functions include a number of metabolic pathways such as homeostatic calcium and iron 
regulation, energy production, apoptosis regulation and generation of reactive oxygen 
species (ROS) (Da Cruz et al., 2003, Youle & Bliek, 2012; Chen & Chan, 2006; Knott et 
al., 2008; Santos & Cardoso, 2012; Moran et al., 2012). 
The extremely protein-rich mitochondrial inner membrane (MIM) encloses the matrix, 
and is organized into folds, or cristae, that house the membrane-bound complexes of the 
electron transport chain, the ATP Synthase (Complex V) and additional electron transport 
proteins such as cytochrome c (cyt c).  The outer mitochondrial membrane (OMM) is a 
smooth phospholipid bilayer that encapsulates the inner membrane and intermembrane 
space.  The OMM is responsible for coordinating mitochondrial function with 
extramitochondrial signaling, thereby regulating mitochondrial dynamics.  Finally, the 
mitochondrial matrix contains the various enzymes that are involved in many of the 
metabolic functions of the organelle (Youle et al., 2012; Krauss et al., 2001; Calabrese et 
al., 2001; Benard & Karbowski, 2010). 
Through differences in permeability between the outer and inner membranes, such that 
the MIM is much less permeable to smaller molecules and ions than the OMM is, 
mitochondria are able to achieve compartmentalization, which is important for many of 
their wide-ranging cellular roles.  By acting both as a molecular barrier and an insulator 
for electrical gradients, the inner membrane is able to facilitate the separation of the 
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mitochondrial matrix and its contents from the cytosol (Youle et al., 2012; Krauss et al., 
2001; Calabrese et al., 2001; Benard & Karbowski, 2010).
1.2.1   Fission and Fusion
Due to their dynamic nature, mitochondria continuously fuse and divide in order to form 
interconnected networks or small individual units within a cell.  These opposing 
processes of fission and fusion are frequent in healthy cells and are adjusted relative to 
cellular needs in order to maintain organelle homeostasis, normal cell function and cell 
survival (Figure 2). 
Fission and fusion dynamics control mitochondrial morphology and function in response 
to cell physiology, developmental state, and a variety of environmental factors.  Proper 
mitochondrial dynamics are essential for the organelle to be able to carry out its many 
metabolic and regulative roles in a number of fundamental eukaryotic processes.  
Additionally, mitochondrial dynamics allow for communication between mitochondria, 
without which the mitochondrial population would become functionally separated and 
impaired (Suen et al., 2008; Lee at al., 2004; Parone et al., 2008; Chen & Chan, 2006; 
Benard & Karbowski, 2009; Chan, 2006).
An imbalance between fission and fusion is closely related to alterations in mitochondrial 
function and ultrastructure, loss of mitochondrial DNA (mtDNA), mitochondrial 
membrane depolarization, and has been linked to several neurodegenerative diseases, 
apoptosis, cancer and ageing. (Muster, 2010; Knott & Bossy-Wetzel, 2008; Wang et al., 
2009; Chen & Chan, 2009; Santos & Cardoso, 2012; Moura et al., 2010; Suen et al., 
2008; Sheridan & Martin, 2010).
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Figure 3. Schematic overview of mitochondrial fission and 
fusion cycles. Under normal cell physiological conditions, 
mitochondria undergo regular maintenance that involves fusion 
mediated by both Mitofusin 1 and 2 (Mfn1/2) and long- and short- 
isoforms of OPA-1 (L/S-OPA1) as well as fission mediated by 
dynamin-related protein 1 (Drp1) and mitochondrial fission protein 
1 (Fis1).  Under conditions of low stress, mitochondria undergo 
stresss-induced mitochondrial hyperfusion (SIMH), which is 
mediated by Mfn1 and L-OPA1 (but not Mfn2 or S-OPA1).  SIMH 
confers stress-resistance to cells by promoting mitochondrial 
biogenesis and increased ATP production.  Under high stress 
conditions, or if low levels of stress are maintained, cells 
eventually succumb to an apoptotic pathway that involves 
increased mitochondrial fragmentation and dysfunction.
Stress-resistance
Cell Death
Figure 2. Schematic overview of mitochondrial  fission and fusion cycles. Under 
normal cell physiological conditions, mitochondria undergo regular maintenance that 
involves fusion mediated by both Mitofusin 1 and 2 (Mfn1/2) and long- and short- 
isoforms of OPA-1 (L/S-OPA1) as well as fission mediated by dynamin-related protein 1 
(Drp1) and mitochondrial fission protein 1 (Fis1).  Under conditions of low stress, 
mitochondria undergo stress-induced mitochondrial hyperfusion (SIMH), which is 
mediated by Mfn1 and L-OPA1 (but not Mfn2 or S-OPA1).  SIMH confers stress-
resistance to cells by promoting mitochondrial biogenesis and increased ATP production. 
Under high stress conditions, or if low levels of stress are maintained, cells eventually 
succumb to an apoptotic pathway  that involves increased mitochondrial fragmentation 
and dysfunction.  This figure is adapted from van der Bliek, 2009.
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The mitochondrial genome is formed by a circular 16,569 base pair DNA that encodes 37 
genes. The majority of these genes code for transfer ribonucleic acids (tRNAs) that are 
required for mitochondrial translational machinery, while the remainder encode 
ribosomal ribonucleic acids (rRNAs) and various subunits of the mitochondrial 
respiratory chain.  The maintenance and replication of mitochondrial DNA (mtDNA) as 
well as the majority of proteins required to maintain proper mitochondrial function, are 
encoded by nuclear DNA and subsequently imported into the mitochondria. Thereby 
exemplifying the intricate relationship between mitochondrial function and whole-cell 
physiology (Moura et al., 2010; Chial & Craig, 2008; Lee & Wei, 2007).
Due to the lack of an efficient DNA repair system and the absence of histones and other 
protective proteins, the mitochondrial genome is much more prone to mutation than the 
nuclear genome.  Synchronized fusion of inner and outer membranes allows for the 
exchange of lipid membrane and mitochondrial contents (e.g. mtDNA) between 
individual mitochondria, thereby intermixing mitochondrial contents and decreasing the 
amount of defective mitochondria within a given population.  Mitochondrial fusion is 
critical for maintenance of the inner mitochondrial membrane potential and is necessary 
for normal respiratory function in cells (Chen et al., 2003; Wang et al., 2009; Tondera et 
al., 2009; Chan et al., 2006; Hoppins et al., 2007; Knott et al., 2008).  Although it is not 
required for mitochondrial fusion itself, an organized cytoskeleton is important for 
distribution, organization and movement of mitochondria so that they may carry out 
organelle fusion (Chan, 2006; Rappaport et al., 1998; Yaffe, 1999; Karbowski et al., 
2001; Knowles et al., 2002; Varadi et al., 2004).  Dysfunctional mitochondrial fusion 
leads to a number of developmental defects in mice and is associated with a number of  
neurodegenerative diseases in humans (Chan 2006; Wakabayashi et al., 2009; Wang et 
al., 2009; Knott & Bossy-Wetzel, 2008).
Fission, conversely, allows for selective elimination of damaged or depolarized 
mitochondria and its contents through mitophagy, thereby also contributing to 
mitochondrial stability and homogeneity within a cell (Chen et al., 2005; Chen, 2006; 
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Twig et al., 2008).  Additionally, mitochondrial fragmentation allows for generation of 
small mitochondria in order to facilitate transport to distant cellular regions where there 
may be a higher energy requirement, and therefore greater necessity for the organelle.  
Finally, mitochondrial fission is integral for segregation of mitochondria between 
daughter cells during mitosis (Moran et al., 2012; Detmer & Chan, 2007; Twig et al., 
2008) and also closely linked to a number of cell signaling pathways during apoptosis.  
Excessive mitochondrial fragmentation is commonly seen when mitochondria are 
dysfunctional (Suen et al., 2008; Tondera et al., 2009; Duvezin-Caubet et al., 2006; 
Guillery et al., 2008). 
Both fission and fusion are regulated by large dynamin-related GTPases that have 
opposing effects (Suen et al., 2008; Bleazard et al.,1999; Sesaki and Jensen 1999; Youle 
and Bliek 2012).  Fusion in mammalian cells depends mainly on mitofusins 1 and 2 
(Mfn1, Mfn2), and OPA1.  The fusion of the outer mitochondrial membrane is controlled 
by the mitofusins, which are localized to the outer mitochondrial membrane, while inner 
membrane fusion depends on OPA1, which is located within the mitochondrial 
intermembrane space (Griparic et al., 2004; Herlan et al., 2003; Olichon et al., 2002; 
Satoh et al., 2003; Wong et al., 2000).  
Mammalian OPA1 was first identified as the gene mutated in autosomal dominant optic 
atrophy (DOA), an inherited form of visual loss through degeneration of retinal ganglion 
cells (Alexander et al., 2000; Delettre et al., 2000).  OPA1 is essential for mitochondrial 
inner membrane fusion, and may also play a role in the control of inner membrane cristae 
structure.  Knockdown of OPA1 has been shown to result in decreased mitochondrial 
fusion accompanied by increased fragmentation and severe abnormalities of 
mitochondrial cristae structure (Chen et al., 2005; Cipolat et al., 2004; Griparic et al., 
2004).  Due to a broad spectrum of splice variants that yield eight mRNA isoforms, as 
well as potential post-translational modifications, the OPA1 gene is able to produce 
multiple protein isoforms (Delettre et al., 2001).  Both long and short isoforms are 
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required in combination to support organized and efficient mitochondrial fusion activity 
(Song et al., 2007).
Fission of the mitochondrial outer membrane requires dynamin-related protein 1 (Drp1) 
and mitochondrial fission 1 protein (Fis1).  The majority of Drp1 is soluble and found in 
the cytoplasm of mammalian cells, while a smaller pool is also found localized to the 
mitochondria in punctate foci, a portion of which will later develop into sites where 
fission will occur (Chan et al., 2006).  Fis1 is an integral outer mitochondrial membrane 
protein and has been shown to functionally interact with Drp1 as an adaptor protein for 
its recruitment from the cytosol to fission cites in order to carry out mitochondrial 
fragmentation (Lu, 2009; Heymann et al., 2009; Liesa et al., 2009; James et al., 2003; 
Yoon et al., 2003).  
Mitochondrial fission and fusion are essential for development in mice as well as 
neuronal survival and function in both mice and humans. Mutations in Drp1 have been 
associated with alterations in its distribution and resultant assembly into cytosolic 
aggregates, while depletion of Drp1 has been linked to immense impairments in 
mitochondria bioenergetics, apoptosis resistance, impaired proliferation, and disrupted 
mitochondrial transport along microtubules (Lee et al., 2004; Benard et al., 2007; Varadi 
et al., 2004).  In yeast, impaired Fis1 function similarly results in defective fission and 
formation of a ‘net-like’ mitochondrial morphology (Suzuki et al., 2005; Karren et al., 
2005). On the other hand, cells lacking integral fusion proteins Mfn1/2 or OPA1 show 
severe cellular defects including diminished growth and decreased levels of oxygen 
consumption through a decline in activity of all five respiratory complexes (Olichon et 
al., 2003; Arnoult et al., 2005; Chen et al., 2005; Lee et al., 2004). Mice lacking these 
fusion proteins die at an early embryonic age (Chen et al., 2003; Davies et al., 2007; 
Tondera et al., 2009).  In humans, point mutations in Mfn2 and OPA1 lead to severe 
neurodegenerative diseases such as Charcot-Marie-Tooth type 2A and DOA, respectively 
(Alexander et al., 2000; Delettre et al., 2000; Zuchner et al., 2004), thereby further 
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illustrating the critical importance of mitochondrial dynamics in neuronal cell function, 
homeostasis, and survival. 
When cells are exposed to selective stresses, including DNA damaging agents or agents 
that inhibit cytosolic protein synthesis, mitochondria undergo a process known as stress-
induced mitochondrial hyperfusion (SIMH).  SIMH involves a subsequent increase in 
mitochondrial biogenesis and ATP production, and presents cells with an adaptive, pro-
survival response to stress.  This is supported by the fact that elongated mitochondria 
tend to display higher efficiency in ATP production which may aid in their ability to 
recover from certain stressful stimuli (Tondera et al., 2009; Rambold et al., 2011).  SIMH 
has been shown to function independently of Mfn2 as well as the prohibitins, an 
evolutionarily conserved family of membrane proteins shown to be involved in cell 
proliferation, cristae morphogenesis and mitochondrial functional integrity (Merkwirth et 
al., 2008). On the other hand, SIMH requires Mfn1, the long isoform of OPA1 (L-OPA1), 
and stomatin-like protein 2 (SLP-2), our protein of interest (Tondera et al., 2009).  SIMH 
is disrupted when cells are treated with chemical inhibitors of oxidative phosphorylation, 
such as CCCP (carbonyl cyanide m-chlorophenyl hydrazone) or oligomycin, which are 
known to disrupt the mitochondrial membrane potential (Tondera et al., 2009), thereby 
further indicating the importance of mitochondrial bioenergetics in this adaptive 
mechanism.  
1.3   Stomatin-like Protein 2 
SLP-2, also known as STOML2 or RPB72, is a widely expressed mitochondrial protein 
found in a number of different tissues and species.  SLP-2 is encoded by an 
approximately 1.5 kilobase mRNA transcribed from a 3250bp gene located on 
chromosome 9p13.  The amino acid sequence for SLP-2 predicts a 38,537 kDA protein 
that shares 20% similarity with stomatin (Da Cruz et al., 2010; Cui et al., 2007; Kirchof 
et al., 2008).  Stomatin, in humans, is a 31kDa erythrocyte membrane protein of unknown 
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function that is suggested to function in the control of ion channel permeability, 
mechanoreception, and lipid domain organization (Cui et al., 2007).  Mice with a 
homozygous null mutation in the murine orthologue of the stomatin gene appear to be 
phenotypically normal (Zhu et al., 1999).  
SLP-2 is a member of the highly conserved stomatin family of proteins, whose 
homologues are widely expressed in different species, and include stomatin, SLP-1, 
SLP-2 and SLP-3 (Dong Chang et al., 2009; Seidel & Prohaska, 1998; Goldstein et al., 
2003; Wang & Morrow, 2000).  Similarly to SLP-2, the precise function of other stomatin 
family proteins is currently unknown. These proteins do, however,  share a common 
stomatin prohibitin flotilin Hflk (SPFH) domain, a signature sequence that implicates 
their enrichment in lipid rafts, as well as their involvement in a number of cellular 
functions.  These functions include protein turnover and cell signaling, assembly and 
regulation of ion channels, lipid domains and mechanosensation receptors, and an ability 
to interact and mediate interactions with cell membranes (Kirchof et al., 2008; Stewart et 
al., 1992; Wetzel et al., 2006; Cui et al., 2007; Hajek et al., 2007; Tavernakis et al., 1999; 
Nadimpalli et al., 2000; Da Cruz et al., 2008, 2010). 
SLP-2 interacts with the peripheral erythrocyte cytoskeleton and other integral membrane 
proteins, but, unlike other members of the stomatin family, not directly with the 
membrane lipid bilayer (Cui et al., 2007).  Instead, SLP-2 is proposed to link integral 
membrane proteins to the peripheral cytoskeleton, and thereby play a role in regulating 
ion channel conductance and organization of lipid rafts (Cui, 2007; Wang et al., 2000).
 SLP-2 has been identified in two major pools throughout cells.  This includes primarily 
an association with the inner mitochondrial membrane, but to a lesser extent also with the 
plasma membrane (Hajek et al., 2006, 2007; Wang et al., 2000; Kirchof et al., 2008; Da 
Cruz et al., 2003; Mootha et al., 2003).  Unlike the other stomatin family proteins, SLP-2 
uniquely lacks a putative amino-terminal hydrophobic transmembrane domain. It does, 
however, contain six myristoylation/palmitoylation sites and an amino-terminal 
mitochondrial targeting sequence, which could explain its attachment to mitochondrial 
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and plasma membranes (Kirchof et al., 2008; Hajek et al., 2006; Owcsarek et al., 2001).  
The primary sequence of SLP-2 does not indicate involvement of an enzymatic domain 
or any traditional protein-protein interaction domain, suggesting that SLP-2  may instead 
form indirect associations through other molecules, and thereby also suggest a role for 
SLP-2 as a potential scaffolding or assembling protein (Kirchof et al., 2008).
SLP-2 forms hetero-oligomers with Mfn2, a large GTPase on the outer mitochondrial 
membrane that is essential for mediating mitochondrial fusion (Hajek et al., 2006; Chen 
et al., 2003; Ishihara, 2004).  One group suggests that other proteins may interact with the 
SLP-2-Mfn2 complex, to form higher molecular weight complexes (Hajek et al., 2006). 
This further implicates a role for SLP-2 as an important scaffolding protein in the inner 
mitochondrial membrane that additionally interacts with fusion machinery on the outer 
mitochondrial membrane.
SLP-2 has been shown to be involved in the regulation of mitochondrial calcium 
homeostasis.  In HeLa cells over-expressing SLP-2, mitochondrial calcium release was 
delayed, while in HeLa cells depleted of SLP-2 by RNA interference (RNAi), this 
calcium release was accelerated (Gouriou et al., 2011; Da Cruz et al., 2010; Palty et al., 
2012).  Additionally, in mouse embryonic fibroblasts (MEFs) SLP-2 is shown to stabilize 
the long (L-) isoform of OPA1 (Tondera et al., 2009), a protein not only required for 
mitochondrial fusion but also for the proper formation of mitochondrial cristae junctions 
(Frezza et al., 2006; Merkwirth et al., 2008; Palmer et al., 2011).  Loss of cristae 
junctions could lead to redistribution of signaling molecules within the inner 
mitochondrial membrane thereby negatively regulating the activity of the mitochondrial 
sodium-calcium exchanger (mNCE) (Da Cruz et al., 2010).  In HeLa cells depleted of 
SLP-2 by RNAi, the levels of calcium in the cytosol were elevated, while in SLP-2 over-
expressing HeLa cells these cytosolic calcium elevations were decreased, suggesting that 
these mitochondrial defects are a cause rather than a result of the cytosolic calcium defect 
(Da Cruz et al., 2010; Gouriou et al., 2011; Palty et al., 2012). 
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Studies in MEFs have shown that SLP-2 is required to stabilize the fusion mediator 
protein L-OPA1 during SIMH, such that this pro-survival response of mitochondrial 
biogenesis does not occur in the absence of SLP-2.  Depletion of SLP-2 results in 
increased proteolytic cleavage of L-OPA1 and inhibited mitochondrial fusion following 
treatment with SIMH-inducing cell stressors.  SLP-2 depletion alone, however, does not 
fragment mitochondria in non-stressed MEFs, but does lead to mitochondrial 
fragmentation in response to various DNA damaging agents, including UV irradiation 
and Actinomycin D.  While SLP-2 depleted MEFs are more prone to mitochondrial 
fragmentation, over-expression of SLP-2 does not appear to alter mitochondrial 
morphology.  The tendency for mitochondria to fragment in SLP-2 depleted cells might 
further contribute to reduced mitochondrial calcium uptake in these cells, because 
mitochondrial fragmentation often leads to relocation of mitochondria away from ER 
calcium release sites, thereby impairing calcium propagation within mitochondria 
(Szabadkai et al., 2004; Da Cruz et al., 2010). 
The overexpression of SLP-2 was first reported in human esophageal squamous cell 
carcinoma (ESCC), with a significant correlation between high SLP-2 expression and 
depth of ESCC invasion, and associated with accelerated cell growth in HEC-1B cells 
(Cui et al., 2007).  SLP-2 is highly expressed in several other types of human cancer 
tissues including lung cancer, endometrium adenocarcinoma, laryngeal squamous cell 
carcinoma (LSCC), and primary invasive breast cancer, wherein high levels of SLP-2 
correlate with distant metastasis, and decreased patient survival (Cao et al., 2007; Dong et  
al., 2009; Zhang et al., 2006).  Furthermore, depletion of SLP-2 in KYSE150 cells (an 
ESCC cell line) by small interfering RNA (siRNA), resulted in increased sensitivity to 
chemotherapeutic reagents by altering the cell cycle without any significant change to 
apoptosis (Wang et al., 2009).  Additionally, depleting the level of SLP-2 expression in 
esophageal cancer cells resulted in reduced cell growth and adhesion, indicating that 
SLP-2 could act as a novel potential oncogene (Cui et al., 2007; Zhang et al., 2005, 2006; 
Dong et al., 2009).
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Consistent with the emerging role of proteins containing an SPFH domain, SLP-2 has 
been shown to divide into lipid rafts, and interact with polymerized actin and T-cell 
receptor signalosome components.  Furthermore, SLP-2 has been shown to contribute to 
human T-cell activation and sustained T-cell receptor signaling, such that changes in 
expression levels of SLP-2 resulted in changes in T-cell activation and responses (Kirchof 
et al., 2008; Christie et al., 2011). Although this may suggest that SLP-2 has the potential 
to act in immunotherapeutics, the role of SLP-2 in neurons and neuronal injury has yet to 
be examined. 
1.4   Mitochondrial Bioenergetics
As mentioned, mitochondria play a large functional role in many cellular processes.  
Their most important function, however, involves the generation of the majority of 
cellular energy in the form of ATP.  ATP production requires the coordinated action of the 
mammalian OXPHOS system, which is composed of five multi-protein complexes 
(Complexes I to V) and two mobile electron carriers, coenzyme Q (CoQ) and cyt c  
(Hatefi, 1986; Lenaz & Genova 2009; Shoubridge, 2012; Muster et al., 2010).  
1.4.1 The Electron Transport Chain
The first four major complexes, which are responsible for the redox portion of this 
process, comprise the respiratory chain (RC) and are located within the mitochondrial 
inner membrane.  These include NADH-CoQ reductase (Complex I, or NADH 
dehydrogenase), succinate-CoQ reductase (Complex II, or succinate dehydrogenase), 
CoQ-cytochrome c reductase (Complex III, or Cytochrome c reductase) and cytochrome 
c oxidase (Complex IV) (Muster et al., 2010; Lenaz & Genova, 2009; Irwin et al., 2012).  
Complex I and II transfer electrons from NADH and FADH2 respectively to coenzyme Q, 
through a series of cofactors, thereby linking the respiratory chain to the tricarboxylic 
acid (TCA) cycle. The reduced coenzyme Q freely diffuses along the membrane to 
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Complex III, which through its ‘Q-cycle’, receives the two electrons from reduced 
coenzyme Q and transfers them individually, through a series of cofactors, to cytochrome 
c.  Finally, Complex IV accepts electrons from cytochrome c and through a series of 
cofactors, transfers electrons to oxygen (O2), the final electron acceptor, thereby reducing 
it to water (H2O) (Vafai et al., 2012; Muster et al., 2010; Balaban et al., 2005).
Complex V of the OXPHOS system is commonly termed the F0F1-ATP synthase as it 
utilizes the proton motive force, of the proton gradient created by the translocation of 
electrons across the inner membrane by the RC, to drive the phosphorylation of ADP to 
ATP (Vafai et al., 2012; Muster et al., 2010; Balaban et al., 2005, Acin-Perez et al., 2008). 
Figure 3 provides a schematic overview and description of oxidative phosphorylation and 
the mitochondrial respiratory chain.
Some of the components of OXPHOS proteins are encoded and produced in the 
mitochondria, however the majority of OXPHOS enzyme complexes are encoded by the 
nuclear genome. Complexes I and III-V consist of multiple polypeptide subunits that are 
encoded by both nuclear and mitochondrial DNA, while Complex II is encoded entirely 
by the nuclear genome (Matsumoto et al., 2012; Irwin et al., 2012; van den Heuvel & 
Smeitink, 2001). The proper biosynthesis of the OXPHOS complexes is therefore a very 
intricate and extremely regulated process that requires coordinated action between the 
two genomes.  Any disturbance in OXPHOS complex biosynthesis can result in 
aggregation of unassembled complexes or other mitochondrial translation products in the 
inner mitochondrial membrane. This would subsequently lead to a mitochondrial electron 
leakage and ROS production, decreased ATP production, and release of apoptosis factors 
ultimately resulting in cell death and potential degeneration of the tissues involved 
(Moran et al., 2012; DiMauro et al., 2009)
Recent structural and functional evidence has suggested that mitochondrial complexes 
associate with one another to form supramolecular structures, known as supercomplexes, 
in order to carry out their roles as “respirasomes” (Acin-Perez et al., 2008).  These 
supercomplexes seem to offer structural and functional benefits to the OXPHOS system 
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by stabilizing and helping to prevent degradation of RC complexes.  This appears to 
improve substrate channeling and electron transport efficiency, and contribute to reduced 
levels of mitochondrial electron and proton leakage (Moran et al., 2012; Koopman et al., 
2010; Lenaz et al., 2010; Wittig et al., 2009).  Due to the structural interdependence 
among RC complexes however, structural changes affecting one particular complex may 
have a significant effect on others.  As a result, genetic deficiency of a single complex 
can result in multiple RC enzyme deficiencies (Acin-Perez et al., 2004; Li et al., 2007; 
Schagger et al., 2001)
Complexes I/III have been shown to form the most abundant and stable supercomplexes, 
particularly in mouse liver mitochondria were the majority of Complexes I and III are 
found in supercomplex form.  Additionally, associations of Complexes III/IV, I/III/IV, II/
III/IV and I/II/III/IV have also been observed, however Complexes II and IV display a 
larger unassociated fraction than the other respiratory complexes.  Some supercomplexes 
additionally include CoQ and cyt c, and retain the ability to transfer electrons from 
NADH or Complex II to oxygen, thereby indicating a functional role for these 
respirasomes (Schagger and Pfeiffer, 2001; Schagger, 2001; Cruciat et al., 2000; Acin-
Perez et al., 2008).  
These reactions, especially those at Complexes I and III, result in formation of ROS, 
which have the potential to become toxic by-products. Mutations in Complex II have also 
been shown to result in ROS production through complex I by way of reverse electron 
flow (Kann et al., 2007; Moura et al., 2010; Chen et al., 2003; Guzy et al., 2008; Moran 
et al., 2012; Murphy et al., 2009).  Additionally, Complex IV itself does not produce 
ROS, however, changes to its state of phosphorylation can lead to production of radicals 
at other points along the respiratory chain (Chen et al., 2003; Kadenbach et al., 2009).
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Figure 3. Schematic overview of oxidative phosphorylation and the complexes of the 
mitochondrial respiratory chain.  All five complexes are embedded in the 
mitochondrial inner membrane (MIM).  The transfer of electrons through Complexes I-
IV (CI-CIV) is coupled to the production of ATP by complex V (CV).   Complexes I and 
II represent entry points for electrons into the respiratory chain.  Complexes I, III, and IV 
transfer protons to the intermembrane space (IMS) thereby  creating an electrochemical 
gradient, and a net negative charge in the mitochondrial matrix.  Complex V utilizes the 
energy of this gradient, while translocating protons back into the mitochondrial matrix, 
for the phosphorylation of ADP to produce ATP.  CoQ and cyt c function as electron 
carriers. This figure is adapted from Perier and Vila, 2012.
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Figure 1. Schematic overview of oxidative phosphorylation and the enzyme complexes of the mitochondrial respiratory chain.  All five 
complexes are embedded in the mitochondrial inner membrane (MIM).  The transfer of electrons through Complexes I-IV is coupled to the 
production of ATP by complex V.   Complexes I and II represent entry points for electrons into the respiratory chain.  Compl xes I, III, and IV 
transfer protons to the intermembrane space (IMS) thereby creating an electrochemical gradient, and a net negative charge in the mitochondrial 
matrix.  Complex V utilizes the energy of this gradient, while translocating protons back into the mitochondrial matrix, for the phosphorylation 
of ADP to produce ATP.  Coenzyme Q (CoQ) and cytochrome c (cyt c) function as electron carriers.  
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1.4.2 Reactive Oxygen Species
ROS collectively refers to the molecular oxygen-derived free radicals and precursors 
formed as a result of incomplete reduction of oxygen.  This includes the superoxide anion 
(O2-), hydrogen peroxide (H2O2) and the hydroxyl radical (HO*).  ROS can be produced 
during oxidative phosphorylation when electrons are captured by oxygen along the ETC 
to produce O2- radicals, and become further converted by manganese superoxide 
dismutase, to hydrogen peroxide.  Hydrogen peroxide can be further broken down within 
the mitochondria, by antioxidant enzymes such as glutathione peroxidase or 
peroxiredoxins, to produce water.  Additionally, cells contain other nonenzymatic ROS 
scavengers including vitamin E, vitamin C, ubiquinone and glutathione to protect them 
from oxidant injury (Uttara et al., 2009; Trachootham et al., 2008; Kushnareva et al., 
2002; D’Autreaux and Toledano 2007).  ROS have the ability to cause functional 
damage, such as reduced coupling and enhanced ROS production, thereby posing a threat  
to the proper function of both mitochondria and the cells they are in, as well as organs 
and an entire organism if left uncontrolled.  Effects of ROS however, are buffered 
through the enzymatic functions of superoxide dismutase and catalase, as well as 
glutathione, thioredoxin and thiol redox buffer systems (Kushnareva et al., 2002; 
D’Autreaux and Toledano 2007).
Although ROS for the most part, are thought to mediate the toxic effects of oxygen due to 
their chemical reactivity, they can also function as important signaling molecules in 
healthy cells.  This however, remains a subject of debate as signaling is thought to require 
precision, and ROS tend to have non-specific, indiscriminate reactivity (Imlay et al., 
2003; D’Autreaux and Toledano, 2007; Halliwell et al., 1999)
Under certain pathological conditions, diminished availability of antioxidants or 
increased radical production can result in an imbalance between ROS production and 
protection, thereby resulting in oxidative stress.  Oxidative stress is used to describe the 
resultant oxidization of proteins, lipids and nucleic acid, and altered cell integrity that 
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follows the excess presence of ROS (Ott et al., 2007; Cherz-Shouval et al., 2007; Van 
Houten et al., 2010)
Mitochondrial DNA is not only more susceptible to ROS damage, but particularly prone 
to mutation due to the absence of protective proteins, such as histones, and a high-
efficiency repair system.  Normal mitochondrial dynamics are suggested to fulfill a ROS-
damage rescue function through their ability not only to intermix defective and functional 
mtDNA through fusion, but also to sequester damaged components through fission and 
subsequent autophagic degradation (Muster et al., 2010).  Chronic mtDNA damage, 
however, can lead to a cycle of decreased synthesis of electron transport chain proteins, 
thereby resulting in increased ROS production, depolarization of mitochondrial 
membrane potential, and decreased ATP production. These factors can result in further 
amplification of oxidative stress and injury in a number of diseased states, and ultimately 
lead to cellular dysfunction and potentially death (Ishii et al., 2006; Van Houten et al., 
2006; Ou et al., 2007; Moran et al., 2012l; Fernandez-Checa et al., 2010).
Additionally, there exists a tightly coordinated feedback loop between ROS production 
and mitochondrial dynamics.  The initial ROS signaling cascade, modulated by 
mitochondrial dynamics, can in turn lead to further scaling of ROS signaling and 
modifications to the level of oxidative stress and damage that can further impact 
mitochondrial dynamics and cell viability.  Mitochondrial ROS production can also act as 
a redox signal in the regulation of  autophagy and apoptosis.  Low levels of oxidative 
damage may induce mitochondrial depolarization which can provide the necessary 
signals for induction of autophagy and thereby result in autophagic removal of potentially 
dangerous radical-producing mitochondria.  If the mitochondrial damage were to occur 
prior to excess ROS production, however, this protective pathway may be impaired, 
resulting in accumulation of ROS-producing organelles and subsequent increase in 
oxidative stress and damage that could eventually result in apoptosis or necrosis instead 
(Yen et al., 2008; Scherz-Shouval and Elazar, 2007; Scherz-Shouval and Elazar, 2011).
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Mitonchondrial response to oxidative stress also seems to be modulated in a dose-
dependent manner, such that at higher concentrations or longer exposure to ROS, 
subsequent increases in the extent of mitochondrial fragmentation and cell death rates are 
observed (Park et al., 2011; Wei and Lee, 2002; ref. Jahani-Asl et al., 2007; Jendrach et 
al., 2008).  Lower ROS doses, on the other hand, appear to induce mitochondrial 
hyperfusion associated with decreased expression of fission protein Fis1, and increased 
expression of fusion proteins Mfn1 and Mfn2 (Yoon et al., 2006 )
Altering the number, density or spatial distribution of mitochondria can modulate a 
process known as ROS-induced ROS release (RIRR).  RIRR refers to the subsequent 
induction of ROS generation in the mitochondria surrounding a smaller population of 
ROS-producing, damaged, or dysfunctional mitochondria, in a given subcellular area.  
RIRR in effect contributes to a whole-cell increase, through mitochondrial propagation, 
in ROS levels, thereby affecting overall cell viability (Park et al., 2011; Zorov et al., 
2000).
The peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) is a potent 
stimulator and major regulator of mitochondrial biogenesis, gene transcription, and 
respiration. As a transcriptional co-activator, PGC-1α functions to transduce 
physiological signals into specific metabolic programs, often through a concomitant 
increase in mitochondrial activity.  This is achieved through activation of nuclear receptor 
ERRα (estrogen-related receptor alpha) and nuclear respiratory factors NRF-1 and NRF-2 
whereby the expression of mitochondrial transcription factor A (Tfam) is regulated 
(Mootha et al., 2004; Wu et al., 1999; St-Pierre et al., 2006; Wareski et al., 2009).  Tfam 
is essential for maintenance, replication, and transcription of mtDNA.  Additionally, 
PGC-1α activates expression of other nuclear encoded proteins required for 
mitochondrial function, including subunits of RC complexes (Wareski et al., 2009).
PGC-1α knockout mice display reduced mitochondrial gene expression, decreased 
metabolic capacity, increased sensitivity to damage caused by oxidative stress (Arany 
2005, Leone 2005, St-Pierre 2006) and behavioral abnormalities secondary to 
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neurodegenerative lesions in the brain (Leone et al., 2005; Lin et al., 2004).  Furthermore, 
this increase in sensitivity to neurodegeneration is associated with increased oxidative 
damage and apoptotic cell death (St-Pierre et al., 2006).
PGC-1α is itself induced by ROS, but it in turn is also involved in regulating cellular 
ROS metabolism through activation of genes encoding mitochondrial ROS-detoxifying 
enzymes, such as mitochondrial superoxide dismutase (SOD) (Kukidome et al., 2006; St-
Pierre et al., 2003; Valle et al., 2005, D’Atreaux and Toledano, 2007).
Currently, there is a substantial amount of evidence linking mitochondrial dysfunction 
and oxidative stress to neurodegenerative diseases such as AD, PD and HD.  Respiratory 
chain dysfunction due to enzymatic or assembly defects, increased ROS production, 
alterations to the morphology of the mitochondrial network and an impaired equilibrium 
between protective cell death are recurrent features of neurodegenerative diseases 
associated with a variety of genetic origins (Enns et al., 2003; Mandemakers et al., 2007; 
Sas et al., 2007; Godvaze et al., 2009; Jellinger et al., 2009).
1.5   Apoptosis
Apoptosis is an endogenously programed form of cell death that is, under physiological 
conditions, active during normal embryonic and postembryonic development and tissue 
homeostasis.  This highly regulated process leads to the organized disassembly of a cell 
and requires active participation of the cell itself (Karbowki et al., 2010; Parone and 
Martinou, 2006; Parone et al., 2006; Desagher et al., 2000; Haeberlein et al., 2004; Suen 
et al. 2008; Youle et al., 2005; Nijhawan et al., 2000).  Apoptosis is essential in multi-
cellular organisms to eliminate unnecessary, ectopic, damaged or mutated cells, and 
consequently the disabling of apoptosis is considered a pathogenic event implicated in 
both oncogenesis and cancer progression. Excessive apoptosis on the other hand, 
especially in postmitotic cells such as neurons or cardiomyocytes, can also be directly 
linked with disease (Youle et al., 2005; Haeberlein et al., 2004).
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Apotosis may be initiated by a number of molecular pathways, the most prominent and 
well characterized known as the extrinsic and intrinsic pathways. The extrinsic pathway 
of apoptosis, also known as the death-receptor-dependent pathway, is triggered by ligand-
induced activation of cell-surface death receptors such as tumor necrosis factor (TNF) 
receptor-1, and the CD95/Fas receptor.  The intrinsic pathway, known as the 
mitochondrial pathway, is on the other hand, triggered by intracellular events, such as 
DNA damage, cytokine withdrawal, oxygen radicals or endoplasmic reticulum (ER) 
stress, and controlled by pro- and anti-apoptotic B cell lymphoma 2 (Bcl-2) family 
proteins. (Otera et al., 2012; Haeberlein et al., 2004; Kroemer et al., 2007; Henry-Mowatt  
et al., 2004).  The mitochondrial pathway is also characterized by mitochondrial 
membrane permeabilization (MMP) and the release of proapoptotic proteins from the 
mitochondrial intermembrane space (IMS) into the cytosol.  These proapoptotic factors 
include cyt c, apoptosis-inducing factor (AIF), Omi, endonuclease G, caspase-9, and 
Smac (Haeberlein et al., 2004; Kroemer et al., 2007; Henry-Mowatt et al., 2004; Parone 
et al., 2006). 
The complete manifestation of apoptosis appears to be highly dependent on activation of 
a specific family of intracellular cysteine-aspartic proteases known as the caspases.  
Caspases generally act as signal transducing molecules grouped into “initiator” caspases 
(e.g. caspases-2, -8, -9 and -10) that function to cleave and thereby activate various 
protein and enzymatic substrates.  These substrates include the second group of “effector” 
caspases (e.g. caspases-3, -6 and -7), which mediate the characteristic widespread protein 
degradation seen during apoptosis. Both extrinsic and intrinsic pathways converge at 
caspase-3, the activation of which promotes the final proteolytic phase of apoptosis 
(Haeberlein et al., 2004, Porter et al., 1999; Henry-Mowatt et al., 2004; Reed and 
Pellecchia, 2005).
The extrinsic and intrinsic pathways of apoptosis are not mutually exclusive, as products 
from the extrinsic pathway can promote activation of the intrinsic pathway.  Caspase-8 
cleavage of Bid to truncated Bid (tBid), for example, allows for the association of tBid 
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with the mitochondrial membrane, thereby stimulating, through Bax/Bak pore formation, 
the release of cyt c. Mitochondria are thus important regulators of apoptosis as they 
represent a convergence point for both extrinsic and intrinsic pathways (Basu et al., 2006; 
Kroemer et al., 2007; Reed and Pellecchia 2005).
Regardless of whether cell death is induced by intrinsic or extrinsic factors, the physical 
and biochemical hallmarks for apoptosis remain the same.  These include cellular 
vacuolization, chromatin condensation and DNA fragmentation, plasma membrane 
blebbing, and cell shrinkage and disintegration into packaged apoptotic bodies that may 
later be engulfed by surrounding phagocytic cells, in order to circumvent inflammatory 
responses. (Kroemer et al 2007; Henry-Mowatt et al 2004; Ly et al., 2003).  
Due to its involvement in tissue homeostasis, apoptosis is controlled at multiple steps 
throughout the process. Mitochondria are important at these apoptotic checkpoints as they 
are involved in integration of a number of signals from both endogenous and exogenous 
factors.  Mitochondria undergo outer MMP when the level of pro-apoptotic signals 
predominate over anti-apoptotic signals, at the level of the mitochondrial membrane 
(Kroemer et al., 2007; Bossy-Wetzel & Green, 1999). 
Apoptotic stimuli, including Bcl-2 family proteins (Bax, Bak, tBid), calcium and 
cytosolic metabolites, and activation of OXPHOS-targeting caspases promote changes in 
mitochondrial transmembrane potential.  The resultant loss of mitochondrial 
transmembrane potential often leads to increased ROS production and concomitant 
saturation of antioxidant systems, thereby hindering mitochondrial function through 
impairment of oxidative phosphorylation and downstream effects on opening of the 
permeability transition pore complex (PTPC).  Opening of the PTPC leads to 
equilibration of ions between the matrix and cytoplasm, resulting in transmembrane 
potential depolarization, ATP hydrolysis, and mitochondrial swelling.  As a result of the 
influx of solutes into the matrix and unfolding of the MIM, the OMM ruptures and 
releases the proapoptotic proteins found within the IMS (Zoratti et al., 1994; Haeberlein 
et al., 2004).  As the mitochondria are responsible for the release of several proapoptotic 
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proteins in response to stress signals, it is critical not only that they are able to perceive 
stress signals properly but also to have proper control over release of these proteins.  
These functions highlight the critical importance of mitochondrial integrity as well as the 
organelle’s critical role in the control of programmed cell death.  
Neurons are cells with limited capacity to replace themselves, and as such, apoptosis in 
neurons subsequent to disease or injury is different from programmed cell death in that it 
ultimately results in a loss of function.  Extensive apoptosis of neuronal cells is observed 
after stroke and trauma, and is the basis for a number of progressive neurodegenerative 
disorders including amyotrophic lateral sclerosis (ALS), PD, and AD. (Nijhawan et al., 
2000; Pettman and Henderson, 1998). 
1.6   Objectives of this thesis
Mitochondrial dynamics play a central role in neuronal injury and several 
neurodegenerative diseases.  The precise physiological role of mitochondrial fission and 
fusion in cell function and survival, however, is poorly understood.  Furthermore, the 
exact mechanisms underlying the pathology of neurodegenerative diseases associated 
with mitochondrial defects are currently unknown.   SLP-2 has been identified as a 
mitochondrial protein reported to interact with and stabilize a number of proteins 
involved in mitochondrial dynamics, and has been implicated in the regulation of 
mitochondrial functions (Da Cruz et al., 2008; Christie et al., 2011; Tondera et al., 2009; 
Artal-Sanz and Tavernarakis, 2009).  In a microarray study examining transcriptional 
changes in neurons, we have found that SLP-2 expression is increased in response to a 
variety of stresses.  Although SLP-2 may contribute to many cell signaling functions 
through its modulation of mitochondrial function and dynamics, the exact role of SLP-2 
in mitochondrial stress responses remains to be discovered.  Given the importance of 
proper mitochondrial function and dynamics to normal neuronal function and 
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neurodegenerative processes, we sought to investigate the role of SLP-2 in neuronal 
injury.   
Through its involvement in mitochondrial dynamics, most notably the hyperfusion stress-
response (SIMH), and interactions with integral mitochondrial proteins, SLP-2 may 
provide a putative link between mitochondrial stress responses, bioenergetics and 
apoptosis.  Thus, we hypothesized that SLP-2 regulates neuron survival in response to 
stressful stimuli.  In order to address this hypothesis, my objectives were to determine the 
effect of altered SLP-2 expression levels, through deletion and up-regulation, on 
mitochondrial biogenesis and function in neurons, and to examine the role of SLP-2 in 
the neuronal stress-response.  The specific aims of this study are to: 1. Examine the 
effects of SLP-2 deletion on primary cortical neurons, and 2. Examine the role of SLP-2 
in neuronal survival under various conditions of stress.
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Chapter 2: Experimental Procedures
2.1 Mice 
Mice heterozygous for the SLP-2 floxed allele (SLP-2lox/wt), were generously provided by 
Dr. Joaquin Madrenas’ Lab at the University of Western Ontario (Montreal, QC).  These 
mice were generated in the C57/BL6 background (Christie et al., 2012).  
2.1.1 Generating forebrain-specific SLP-2 knockout mice
Germline deletion of SLP-2 results in embryonic lethality at the pre-implantation stage 
(Christie et al., 2012).  Therefore, we employed a conditional Cre/loxP recombination 
method (Kuhn & Torres, 2002; Le & Sauer, 2000) to generate a conditional SLP-2 
knockout mouse (Appendix A).  
SLP-2lox/wt mice were bred to produce mice that were homozygous for the SLP-2 floxed 
allele (SLP-2lox/lox).  PCR analysis (Section 2.9) was employed to confirm the genotype of 
SLP-2lox/lox mice, which were then crossed with C57BL/6 mice transgenic for Cre 
recombinase under the control of the Brain Factor-1 (Foxg1) promoter.  Brain Factor-1 
(BF-1) is specifically expressed in the telencephalon, beginning at around E9.5, and 
persisting in the adult brain in structures derived from the telencephalon including the 
cerebral cortex, hippocampus, and basal ganglia (Hebert and McConnell, 2000; Ferguson 
et al., 2002).  Therefore, this model allows for forebrain-specific expression of the Cre 
gene, as it develops in the mouse embryo.   The offspring of this breeding pair (SLP-2lox/
lox x SLP-2wt/wt/Cre) were thus selected for both heterozygous expression of the floxed 
SLP-2 allele and expression of Cre recombinase (SLP-2lox/wt/Cre).  SLP-2lox/wt/Cre mice 
were then crossed with SLP-2lox/lox mice, by pairing males and females for a timed period 
of 3-days, in order to obtain forebrain-specific SLP-2 knockout embryos (SLP-2lox/lox/Cre) 
at E14.5-15.5 (Appendix A). 
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2.2   Genotyping
Tail samples from each mouse or embryo were placed in a separate 1.5mL 
microcentrifuge tube and dissolved in a solution of 500µL DNA Lysis buffer [DNA LB; 
100mM Tris buffer, 5mM EDTA, 0.2% SDS, 200mM NaCl] and 10µL of 0.2 mg/mL 
Proteinase K (Invitrogen), and placed over night on a 55℃ heat block to ensure proper 
digestion.  
To extract the DNA, 500µL phenol-chloroform [phenol:chloroform:iso-amyl alcohol 
(25:24:1)] was added to each tail sample.  Samples were shaken thoroughly for 1 minute  
and centrifuged at room temperature at 12,000xg for 10 minutes.  The upper aqueous 
phase was then transferred to a new set of tubes, while carefully avoiding contamination 
with the interphase.  Following addition of 500µL of cold 95% isopropanol, each tube 
was shaken vigorously until a DNA precipitate was seen.  Tubes were centrifuged at 
12,000xg for 10 minutes at 4℃.  Next, the supernatant was carefully aspirated and 1mL 
of 70% ethanol was added to each tube to rinse the DNA pellet.  Samples were 
centrifuged 12,000xg for 5 minutes at 4℃.  The excess supernatant was removed, leaving 
the DNA pellet damp, and tubes were left open for 10 minutes on a 55℃ heat block to 
allow the remainder of the ethanol to evaporate.  Upon drying, pellets were resuspended 
in 40µL 1x TE buffer (pH 8.0) and incubated for 20 minutes on a 55℃ heat block to 
ensure the DNA completely dissolved.  DNA was quantified using a NanoDrop 1000 
Spectrophotometer (Thermo Scientific).  
2.2.1   Polymerase Chain Reaction
Polymerase chain reaction (PCR) was employed to genotype each sample.  The reagents, 
cycling conditions, and expected products for each PCR reaction are outlined in 
Appendix B.  Once the PCR was complete, each sample was loaded, along with a 1kb+ 
ladder (Fermentas) onto a 1.5% agarose gel bathed in 1 x TAE buffer.  The gel was run 
for 40 minutes at 130V, and PCR products were visualized using a Gel Doc imager 
(BioRad) under UV light.
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2.3 Cell culture
2.3.1 Primary Cortical Neurons
Primary cortical neurons were dissected from E14.5-15.5 mouse embryos of timed 
pregnant SLP-2lox/lox mice that had been crossed with an SLP-2lox/wt/Cre male (or pregnant 
SLP-2lox/wt/Cre mice that had been crossed with an SLP-2lox/lox male) (Section 2.1, 
Appendix A).  An intra-peritoneal injection of euthanyl was used to sacrifice the female.  
Embryos were dissected immediately after and placed in 1x Hanks’ Balanced Salt 
Solution (HBSS; Gibco®, 14170-112).  A dissecting microscope was used to visualize the 
embryos in order to dissect and remove the meninges from cerebral cortices.  Cerebral 
cortices were kept separate for processing due to variances in genotype.  A tail sample 
and the remainder of the brain of each embryo were also retained separately for 
genotyping purposes.
To dissociate the cortical neurons, individual cortices were trypsinized with 300µL of 
HBSS solution supplemented with 1.2 mM MgSO4 and 75 mg/mL trypsin (Sigma), and 
placed in a 37℃ incubator, on a rotor, for 25 minutes.  To halt trypsinization, 600µL of a 
HBSS solution supplemented with 1.2mM MgSO4, 0.25 mg/mL DNase I, and 0.2 mg/
mL trypsin inhibitor was added to each sample and mixed thoroughly by inversion for 2 
minutes.  Next, the cell solutions were centrifuged for 5 minutes at 400xg and the 
supernatant was carefully removed.  The remaining cell pellets were resuspended in 
HBSS solution supplemented with 3mM MgSO4, 1mg/mL trypsin inhibitor and 
0.65mg/mL DNase I.
To ensure dissociation, the cells were triturated 15-20 times through a flame polished 
glass pipette, and then centrifuged at 400xg for 5 minutes.  The supernatant was carefully 
aspirated and the cell pellets were resuspended in 2mL complete neurobasal media 
(NBM; Gibco®, 21103-049) [C-NBM; 1x B27 and N2 supplements, 1mM glutamax, and 
50 U/mL penicillin:50µg/mL streptomycin].
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Cell density was determined using Trypan Blue (Invitrogen) and a haemocytometer under 
a light microscope.  Cell suspensions were diluted in C-NBM to a concentration of 1 
million cells/mL and plated in either 60mm (5mL; 5x106 cells/dish), or 4-well (500µL; 
3x106 cells/well) dishes.  All dishes were previously coated with poly-L-ornithine 
(Sigma) (diluted 1:10 in ddH2O) and cultures were maintained in a humidified 37℃ 
incubator with 5% CO2.  
2.3.2 SN56 Neuronal Cell Line
SN56 cells were generously provided by Dr. Jane Rylett (Hammond et al., 1986; Le et al., 
1997; Blusztajn et al., 1992).  The SN56 neuronal cell line is a hybrid cell line resulting 
from the fusion of dissociated embryonic mouse septal neurons with murine 
neurobastoma (N18TG2) cells.  These cells were maintained in complete  Dulbecco’s 
Modified Eagle Medium (DMEM: Gibco®, 11965-092) [C-DMEM; 10% FBS,  
Gentamicin, and in 50 U/mL penicillin:50µg/mL streptomycin] in T-75 flasks (Thermo 
Scientific) and passaged every 3-4 days at 1:10.  For experiments, SN56 cells were plated 
at 1:15 on either 4-well or 60mm dishes.  After a minimum of 24 hours, when SN56 cells 
had attached to the bottom of the dish, C-DMEM was aspirated and replaced with serum-
free DMEM [SF-DMEM], in order to induce differentiation.  SF-DMEM was replaced 
each day in order to induce differentiation-associated changes including decreased cell 
division and extensive neuritic outgrowth.  These changes were consistent with those 
documented in previous studies of SN56 cells (Barbosa et al., 1999; Blusztajn et al., 
1992).  The cultures were maintained in a humidified 37℃ incubator with 5% CO2. 
2.3.3 Plasmids
Green fluorescent protein (GFP) cDNA and fused SLP-2-GFP cDNA were cloned into 
CMV-promoter based vectors (pcDNA3, Invitrogen), to generate pEGFP and pSLP-2-
GFP plasmids that would fluoresce green upon protein expression.  Stable transfectants 
were generated by nucleofection. 
31
2.3.4 Transfection
A Calcium Phosphate transfection method was employed to transfect differentiated SN56 
cells, with either pEGFP or pSLP-2-GFP. Stock solutions of 1x HBS [1x HBS; 5g 
HEPES Acid, 8g NaCl, 1g Dextrose, 3.7g KCl, 10mL Na2HPO4(7H2O), 890mL ddH2O. 
pH 7.1] and 2.5M CaCl2 [2.5M CaCl2 ; 27.75g anhydrous CaCl2, 100mL ddH2O] were 
prepared prior to transfection and stored at -20℃, while a working tube was kept at 4℃.
The following table denotes the amount of DNA and each reagent used relative to the 
surface area of the dish being treated. DNA was diluted in ddH2O to a final volume of 
15mL for each transfection.
Table 1. DNA and Reagent Amounts for Calcium Phosphate Transfection Method
Dish Culture  Media 
1x 
HBS
2.5M 
CaCl2 DNA
4-well 500µL 18µL 1.1µL 1.1µg
60 mm 5mL 186µL 11µL 11µg
For each transfection, DNA was added to 1x HBS in a 1.5mL microcentrifuge tube and 
mixed thoroughly.  Next, 2.5M CaCl2 was added to the tube in a dropwise fashion and 
mixed carefully by inversion.  The transfection mix was then added to plates in a 
dropwise fashion.  Dishes were put back in a humidified 37℃ incubator at 5% CO2.  
Serum-free DMEM was changed after 16 hours and cells were either treated or harvested 
48-72 hours later, once 30-40% transfection efficiency was reached.   
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2.4 Protein Extraction and Quantification
Following respective treatments and at appropriate time points, culture media was 
carefully removed from adhered cells on 60mm dishes.  Cells were then washed twice 
with cold PBS and 100µL complete RIPA (Sigma) Lysis Buffer [RIPA: 100µL protease 
inhibitor cocktail (Sigma), 900µL RIPA Lysis Buffer (Sigma)] was added directly onto 
each culture dish.  A cell scraper was used to carefully remove cells from each dish, and 
the resultant lysates were each passed through a pipette 5 times.  The lysates were then 
transferred to separate 1.5mL microcentrifuge tubes and placed on ice for at least 20 
minutes.  The resulting mixture was centrifuged at 14,000xg for 12 minutes at 4℃.  The 
supernatant from each tube was transferred to a fresh 1.5mL microcentrifuge tube and 
stored at -80℃ until further analysis.
The Pierce® BCA Protein Assay Kit (Thermo Scientific) was used, according to 
manufacturer’s protocol, to determine the protein concentration of each sample.  The 
absorbance at 562 nm was measured using the SpectraMax® M5 Multi-Mode Microplate 
Reader (Molecular Devices) and SoftMaxPro V5 (Molecular Devices) software.  A 
standard curve was generated by plotting absorbance at 562 nm versus concentration of 
BCA.  The concentrations of the protein samples were then calculated by inserting their 
absorbance values into the equation of the standard curve.
2.5 Western Blot Analysis
Thirty micrograms of each protein sample were mixed with different volumes of 
complete RIPA Lysis Buffer in order to obtain a constant sample volume.  Next, 1x SDS 
was added to each sample and the mixtures were heated at 37-100℃ (depending on the 
protein of interest) for five minutes to reduce disulfide bonds and denature proteins.  The 
samples were then loaded onto a 1.5mm 12% polyacrylamide mini-gel (Bio-Rad) and run 
at 100-125V.  The protein was then transferred to a nitrocellulose membrane via semi-dry 
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electroblotting.   The nitrocellulose membrane was then stained with Ponceau S (Sigma) 
to visualize total protein present, and then cleaned thoroughly by rinsing three times for 5 
minutes with a wash buffer solution [WB: 150mM NaCl, 10mM Tris, and 0.05% 
Tween-20].   
Next, the nitrocellulose membrane was incubated in a 5% blocking solution [5% 
powdered milk (w/v) in WB] for 1 hour at room temperature, after which the blocking 
solution was replaced with primary antibody diluted in a 5% wash buffer solution [%5 
(w/v) powdered milk in WB], and incubated on an orbital shaker overnight at 4℃.  All 
primary antibodies were diluted in 5% wash buffer solution.  Primary antibodies used 
were rabbit polyclonal Calnexin antibody [1:500; Santa Cruz (H-70)], rabbit polyclonal 
Actin antibody [1:10,00; Santa Cruz (I-19)], mouse Total Oxidative Phosphorylation 
monoclonal antibody cocktail [1:250; Mito Sciences #MS604], mouse monoclonal 
NDUFS3 antibody [1:500; Abcam #14711], mouse monoclonal TOMM20 antibody 
[1:500; Abcam #56783] and rabbit polyclonal SLP-2 antibody [1:500; ProteinTech (1-
AP) #10348].  Next, membranes were incubated with a secondary antibody diluted in 3% 
wash buffer solution [3% (w/v) powdered milk in WB] for 1 hour at room temperature.  
All secondary antibodies were diluted in 3% wash buffer solution.  Secondary antibodies 
used were horseradish peroxidase (HRP)-conjugated goat anti-rabbit (GAR) IgG (H+L) 
[1:10,000, Bio-Rad] and goat anti-mouse (GAM) IgG (H+L) [1:10,000, Bio-Rad].  
Excess secondary antibody was washed away with three 5 minute washes with WB.  The 
membrane was then coated with a 1:1 mixture of Stable Peroxidase Solution and 
Luminol/Enhancer Solution from a SuperSignal® West Pico Chemiluminescent Substrate 
Kit (Thermo Scientific) for 5 minutes and then dried and wrapped with Saran wrap.  
Kodak BioMax maximum sensitivity film was pressed against the membrane in a dark 
room for 10 seconds to 15 minutes, depending on the antibody.  Films were developed 
with a Micro-Max X-Ray Automatic Film Processor (Hope).
34
2.6   RNA extraction and Quantification
Culture media was carefully removed from adhered cells on 4-well or 60mm dishes.  
RNA was extracted from both primary cortical neurons and SN56 cells using Trizol® 
(Invitrogen) reagent, according to the manufacturer’s protocol.  
RNA was quantified using a NanoDrop 1000 Spectrophotometer (Thermo Scientific).  
Each sample was measured in duplicate, and the average concentration was calculated.
2.7   Quantitative RT-PCR
RNA samples were diluted to a working concentration of 10ng/µL in RNAse/DNAse free 
H2O (Gibco).  The reagents, cycling conditions, and expected products for each 
quantitative real-time polymerase chain reaction (qRT-PCR) reaction may be found in 
Appendix B.  Primer probes were selected for the housekeeping gene, ribosomal S12, 
which served as a comparison for the other genes that were analyzed.  Four microliters of 
each RNA sample was mixed with 21µL of Master Mix for each primer probe.  Samples 
were run on a Peltier-Thermal Cycler 200 connected to a Chromo 4 Continuous 
Fluorescence Detector (MJ Research) and data acquisition software Opticon Monitor 3.  
PCR efficiency was >90% for all amplicons.  Melting curve analysis revealed a single 
peak indicating a single RT-PCR product for each gene, and products were confirmed via 
sequencing to determine primer specificity.  The difference in target gene expression was 
calculated using the Delta-Delta CT Method, as per the following equation:
         (Etarget) ∆CTtarget (control-sample)     
     ratio  =  
              (Eref) ∆CTref (control-cample)
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2.8   Drug treatments
Drug treatments were administered on day 5 in culture for primary cortical neurons and 
48-72 hours following transfection in SN56 cells.  Each drug was diluted with media 
from a stock solution to a desired treatment concentration.  A non-competitive NMDA 
receptor antagonist, MK-801, was added to all treatments, except Camptothecin (CPT), in 
order to prevent secondary excitotoxic cell death.  Details regarding each drug used are 
summarized in the following table:
Table 2. Drugs Used for Stress Treatments Experiments
Drug Name Effects Company Cat # Stock [ ] Solvent Final [ ]
1-methyl-4-
phenylpyridinium 
(MPP+)
Complex I (NADH 
dehydrogenase) 
inhibitor
Sigma D048 100mM Water 5-200µM
3-Nitropropionic 
Acid (3-NP)
Complex II 
(succinate 
dehydrogenase) 
inhibitor
Sigma N5636 1M Ethanol 0.5-10µM
Camptothecin 
(CPT)
DNA damage - 
Topoisomerase I 
inhibitor
Sigma C9911 10mM DMSO 40µM
MK-801 NMDA antagonist Sigma M107 10mM Water 10µM
2.9   Cell death assessment
2.9.1   Primary Cortical Neurons
Following 24 hours treatment of 4-well dishes with either MPP+, 3-NP, or CPT, a Live/
Dead Assay (Invitrogen) for cell viability was employed to assess the percentage of dead 
cells in a given cell population.  Live cells have intracellular esterases that convert non-
fluorescent, cell permeable calcein acetoxymethyl to a fluorescent (green) calcein.  Dead 
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cells, as a result of having damaged membranes, allow for the ethidium homodimer-1 to 
enter damaged cells and fluoresce (red) upon binding to nucleic acid.   
An Olympus IX70 Fluorescence Microscope, and Northern Eclipse software (v. 7.0) were 
used to perform imaging.  Images were captured on 5-6 random locations per well at 
400X magnification.  Using ImageJ software, at least 500 cells were counted per 
treatment in each experiment.  The percentage of cell death was calculated by dividing 
the number of dead (red) cells by the total number of cells (red and green).
2.9.2   SN56 Cells
Following 24 hours treatment of 4-well dishes with either MPP+ or CPT, cells were 
stained with Hoechst 33342 (1µM) dye (Sigma), incubated at 37℃ for an optimized time 
of 15 minutes to minimize signal bleeding, and imaged immediately using fluorescence 
microscopy and Northern Eclipse 7.0 software. Images were captured on 5-6 random 
locations per well at 400x or 600x magnification.  Using ImageJ software, at least 500 
cells were counted per treatment in each experiment.  Cells were considered apoptotic if 
nuclei displayed highly condensed chromatin that was uniformly and brightly stained by 
Hoechst 33342 (See Appendix D).  Only GFP-positive cells (plasmid-expressing) were 
counted when assessing the percentage of apoptosis, which was calculated by dividing 
the number of apoptotic nuclei by the total number of healthy and apoptotic nuclei 
counted for each treatment.
2.10   Immunofluorescence
Primary cortical neurons and SN56 cells were plated on to 4-well dishes containing cover 
slips (coated with poly-L-ornithine for primary cortical neurons) and cultured in a 
humidified 37℃ incubator with 5% CO2.  Following treatment, culture media was 
carefully removed from adherent cells and replaced with 500µL Lana’s Fixative [LF; 4% 
paraformaldehyde, 0.2% picric acid] for 20 minutes at room temperature.  After the cells 
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had been fixed, they were rinsed three times in cold PBS.  Cells were permeabilized with 
a mixture of 0.1% Triton prepared in PBS (pH 7.4) for 10 minutes.  After three 5 minute 
washes with PBS, cells were treated with Blocking Solution [0.2% Triton X, 1x PBS] for 
at least 1 hour.  The cells were then incubated with 500µL of primary antibody, diluted 
1:500 in Antibody Diluent [1x PBS containing 0.2% Triton-X and 2% BSA], and stored 
overnight at 4℃.  The next day, this solution was carefully aspirated and after three 5 
minutes washes with 1x PBS, cells were incubated with a secondary antibody against 
mouse IgG [AlexaFluor 568 rabbit anti-mouse IgG (H+L) HRP conjugate; Molecular 
Probes], diluted 1:1000 in Antibody Diluent, for 1 hour at room temperature.  To stain 
nuclei in fixed cells, samples were incubated with Hoechst 33358 (1µM) for 15 minutes 
at room temperature.  After washing with 1x PBS, coverslips were carefully removed 
from 4-well dishes and placed cell-side down on slides with ImmuMount (Thermo 
Scientific).  Cells were imaged using an Olympus IX70 Fluorescence Microscope, and 
Northern Eclipse software (v. 7.0).
2.11   Flow Cytometry
Primary cortical neurons, on day 5 in culture, were labeled with 10nM MitoTracker Red® 
CMXRos (Invitrogen),  and incubated at 37℃ for 20min.  MitoTracker Red® CMXRos 
(MtkrRed) is a red-fluorescent dye that stains mitochondria in live cells.  Once the 
mitochondria were labeled, C-NBM (Section 2.2.1) was carefully aspirated off of the 
adherent cells and diluted Ethylenediaminetetraaceitc acid [0.2% EDTA in 1x PBS] was 
used to remove adherent cells from each plate.  
EDTA is a calcium chelator that binds Ca2+ ions which are required for cells to maintain 
adhesion.  After 5 minutes, C-NBM was added to each plate to neutralize the EDTA, and 
samples were placed in separate 15mL conical centrifuge tubes and centrifuged at 100xg 
for 3 minutes.  The supernatant was aspirated, the cells were rinsed with PBS, and the 
solution was centrifuged again at 100xg for 3 minutes.  The supernatant was aspirated 
again, each sample was resuspended in 1mL PBS, and tubes were immediately covered in 
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foil and placed on ice.  Fluorescence was detected by flow cytometry using the BD 
AcuriTM C6 Flow Cytometer (Biosciences) and FACS analysis was conducted using the 
accompanying BD AcuriTM C6 Software (Biosciences).  
2.12    Brain Slice Preparation 
2.12.1     Mouse Brain Perfusion and Preparation
Adult brains of age-matched (P70) litter mate mice were dissected following a standard 
protocol for perfusion fixation with 4% paraformaldehyde (PFA) through the heart (Gage 
et al., 2012). The brains were stored at 4℃ in 4% PFA.  Twenty four hours prior to 
sectioning, 4% PFA was replaced with a 30% sucrose solution [30% sucrose (w/v) in 4% 
PFA].   Cryostat frozen sectioning was used to produce thin (40µm), uniform, brain 
slices.  Brain slices were stored in PBS at 4℃, until they were mounted on slides and 
prepared for staining.
2.12.2    Cresyl Violet Staining
Once placed on slides, brain slices were left to air-dry at room temperature for 6-8 hours, 
in order to encourage adherence of the tissue to the slide.  Next, the slides were 
rehydrated with ddH2O, and then submersed in Cresyl Violet Stain [CVS; 0.1% Cresyl 
Violet Acetate (w/v), 0.25% Glacial Acetic Acid (pure), ddH2O] for 3-4 minutes.  Excess 
stain was rinsed off in ddH2O.  Slides were dipped in 70% Ethanol for 2 minutes, 
followed by 95% Ethanol for 2 minutes, 100% Ethanol for 2 minutes, and Xylene for 2 
minutes.  Tissues were covered with ImmuMount (Thermo Scientific) and a cover slip, 
and dried overnight at room temperature.  Slides were imaged using a Zeiss LSM 510 
Meta Confocal Microscope and Zeiss LSM digital imaging software.
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2.13    Statistical Analysis
All results are reported as mean and standard error (± SE).  Each value represented for 
‘n’ indicates an individual cortical neuronal culture or SN56 passage of the indicated 
genotype.  A one-way analysis of variance (ANOVA) followed by Tukey’s multiple 
comparison test was used to determine whether differences between more than three 
sample means were significant (Figures 6, 9, 11, 16, and 18).  An unpaired Student’s t test 
was used to determine whether differences in RNA levels, Mitotracker Red fluorescence, 
and expression of SLP-2 protein and levels of electron transport chain proteins were 
significant when comparing wild-type and SLP-2 knockout cortical neurons under basal 
conditions (Figures 8, 10, 11 and 18).  A P value less than 0.05 was considered 
significant, and all statistical analyses were conducted using GraphPad Prism software 
version 6.0.
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Chapter 3: Results
3.1    Experimental model for generating SLP-2-deficient primary cortical
         neurons
3.1.1    Successful knockout of SLP-2 gene 
Germline SLP-2 deletion results in embryonic lethality in mice (Christie et al., 2012).  
We therefore employed a conditional knockout approach to study the effects of SLP-2 
depletion in mouse primary cortical neurons (See section 2.1 and Appendix A).  Under 
the control of the Brain Factor-1 (FoxG1) specific promoter, Cre recombinase coupled 
with a genome-wide loxP insertion flanking the SLP-2 gene (SLP-2lox) was expected to 
result in a forebrain-specific knockout of the SLP-2 gene as it develops in the mouse 
embryo.  With our results, we were able to demonstrate successful knockout of SLP-2 in 
E14.5-15.5 forebrain cortical neurons of SLP-2lox/lox/Cre mice (Figure 4).
Although conditional gene targeting by the Cre/loxP system is considered an effective 
method of specific gene excision, cre transgene recombination efficiency has been shown 
to possess variability and unexpected expression patterns depending on the target gene.  
In both the male and female germlines, cre may mediate non-homogeneous mutations 
aside from the desired conditional mutation.  In most cases, this results when both the 
loxP allele and the cre allele are inherited from the same parent (Schmidt-Supprian & 
Rajewski, 2007).  Given that our breeding paradigm is at risk of this phenomenon, and 
that a germline deletion of SLP-2 on one allele would not be detected with either SLP-2lox 
or SLP-2wt primers, we generated a primer for an ‘SLP-2 deletion’ allele (SLP-2del; see 
Appendix B for sequence), to confirm specificity of the conditional knockout model 
herein employed, and ensure proper genotyping of each sample.   
Additionally, in order to confirm that the ‘wild-type’ (SLP-2lox/wt) employed in our 
experiments was comparable to a wild-type mouse lacking the flanked sequences, an 
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SLP-2wt/wt/Cre mouse was crossed with a mouse heterozygous for the SLP-2lox allele 
(SLP-2lox/wt).  Tail samples obtained from E14.5-15.5 mice were used to extract DNA and 
determine genotypes by PCR and agarose gel electrophoresis analysis (Figure 4a).  
Whole cell protein lysates were prepared from primary cortical neurons on day 5 in 
culture and compared by Western Blot analysis (Figure 4b).  As a result we were able to 
compare relative SLP-2 protein expression in ‘wild-type’ genotypes and confirm SLP-2 
deletion in our conditional knockout mouse model (Figure 4b).    
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Figure 4. Confirmation of SLP-2 deletion.  (a) Representative agarose gel (1.5%) electrophoresis illustrating PCR products for i) Cre 
recombinase (Cre) and ii) SLP-2 wild-type (SLP-2 wt), SLP-2 floxed (SLP-2 lox) and SLP-2 null (SLP-2 del) alleles.  Genotype is 
provided by combining results from lanes corresponding to the same number: Lane 1) SLP-2 knockout (SLP-2lox/del/Cre); 2)SLP-2 
knockout (SLP-2lox/lox/Cre); 3) homozygous floxed SLP-2 not expressing Cre (SLP-2lox/lox), 4) heterozygous floxed SLP-2 not 
expressing Cre (wild-type, SLP-2lox/wt) 5) heterozygous floxed SLP-2 expressing Cre (SLP-2lox/wt/Cre).  (b) Representative Western blot 
analysis of SLP-2 protein expression.  Whole cell lysates were prepared from primary cortical neurons on day 5 in culture. SLP-2lox/wt 
corresponds to the wild-type genotype employed in our experiments as control; SLP-2wt/wt corresponds to a wild-type C57/BL6 mouse 
lacking the SLP-2lox mutation; Cre+ mice express Cre recombinase under the control of a brain factor-1 specific promoter.  Calnexin 
expression served as a loading control.
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Additionally, in order to confirm that the ‘wild-type’ (SLP-2lox/wt) employed in our experiments 
was comparable to a wild-type mouse lacking the flanked sequences, an SLP-2wt/wt Cre+ mouse 
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To study the effects of enforced expression of SLP-2, we adopted a SN56 neuronal cell line.  
These cells are a hybrid cell line resulting from the fusion of dissociated embryonic mouse septal 
neurons with murine neuroblastoma (N18TG2) cells. When differentiated, SN56 cells possess 
neuronal morphology and a cholinergic phenotype [31].
Two-day serum withdrawal was employed to induce differentiation in SN56 cells. Subsequently, 
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Figure 4. Confirmation of SLP-2 deletion.  (a) Representative agarose gel (1.5%) 
electrophoresis illustrating PCR products for i) Cre recombinase (Cre) and ii) SLP-2 
wild-type (SLP-2 wt), SLP-2 floxed (SLP-2 l x) and SLP-2 null (SLP-2 del) alleles. 
DNA extracts were prepared from tail samples obtained at E14.5-15.5.  Ge otype is 
provided by combining results from lanes corresponding o th  same number: Lane 1) 
SLP-2 knockout (SLP-2lox/del/Cre); 2)SLP-2 knockout (SLP-2lox/lox/Cre); 3) homozygous 
floxed SLP-2 not expressing Cre (SLP-2lox/lox), 4) heterozygous floxed SLP-2 not 
expressing Cre (wild-typ , SLP-2lox/wt) 5) heterozygous f oxed SLP-2 expressing Cre 
(SLP-2lox/wt/Cre).  (b) Representative Western blot analysis of SLP-2 protein expression. 
Whole cell lysates were prepared from primary cortical neurons on day  5 in culture. 
SLP-2lox/wt corresponds to the wild-type genotype employed in our experiments as 
control; SLP-2wt/wt corresponds to a wild-type C57/BL6 mouse lacking the SLP-2lox 
mutation; Cre+ mice express Cre recombinase under the control of a brain factor-1 
specific promoter.  Calnexin expression served as a loading control.
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3.2   Analysis of the effects of SLP-2 deletion on primary cortical neurons
3.2.1   Forebrain morphology in wild-type and SLP-2 knockout mice
Macroscopic examination of brains from age-matched litter-mate wild-type (SLP-2lox/wt) 
and knockout (SLP-2lox/lox/Cre) adult (P70) mice revealed no major abnormalities.  
Additionally, coronal cryostat sections (40µm) were prepared from the cerebral cortex, 
and labelled with Cresyl Violet Acetate (CVA).  CVA is a basic aniline dye that binds 
readily to acidic components of neuronal nuclei and cytoplasm, thereby highlighting 
important neuronal features such as the rough endoplasmic reticulum (Nissl bodies) and 
nuclei.  Representative confocal images (Figure 5) reveal similar cell layering and 
morphology in forebrains of SLP-2 knockout and wild-type mice. 
3.2.2   Neuron viability under normal cell culture conditions
In order to assess and compare cell viability between SLP-2 knockout (SLP-2lox/lox/Cre) 
and wild-type (SLP-2lox/wt) primary cortical neurons, a Live/Dead Assay (Invitrogen) was 
employed to obtain data for the percentage of cell death in cell cultures at days 3, 5, and 7 
under standard culture conditions [37℃ humidified incubator, 5% CO2, C-NBM].  The 
analysis was repeated five times for each genotype and day in culture, and results were 
analyzed using a one-way ANOVA and Tukey’s multiple comparisons test.  There was no 
significant difference (P> 0.05, n=5) in the percentage of cell death between SLP-2 
knockout and wild-type (control) cultures at either time point (Figure 6).
3.2.3   Neuritic outgrowth
Dendrite development and synapse formation are important for and indicative of proper 
neuronal function as they allow neurons to form functional networks and communicate 
between each other.  In order to visualize neuritic outgrowth in both SLP-2 knockout 
(SLP-2lox/lox/Cre) and wild-type (SLP-2lox/wt) primary cortical neurons, cells were labeled 
with anti-microtubule-associated protein 2 (MAP2).  Proteins of this family are thought 
to be involved in microtubule stabilization and assembly, which are essential for the 
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development and maintenance of proper neuronal morphology (Matus et al., 1981; 
Caceres et al., 1984, 1986; Peng et al., 1986).  Representative fluorescence images 
(Figure 7) demonstrate that both SLP-2 knockout and wild-type cortical neurons are 
MAP-2 positive, and display competent neuritic outgrowth and dendrite formation. 
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Figure 10. Histology of adult (P70) wild-type (SLP-2lox/wt) and SLP-2 knockout (SLP-2lox/lox/Cre) mouse forebrains. Representative confocal 
images of cresyl-violet-stained coronal hemi-sections (40µm) through cerebral cortex at different rostral forebrain levels. Cell layering (1-6) appears 
normal in both wild-type (c) and SLP-2 knockout (f) cortices, and cryomorphology appears unaltered in both wild-type (a and b) and SLP-2 knockout 
(d and e) rostral forebrains. (c) and (f) are magnified images of sections outlined in (b) and (e) respectively. CP: caudate putamen; LV: left ventricle; 
RV: right ventricle; Sep: septum. Scale bars: 1mm.
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Figure 5. Hi tology of adult (P70) wild-type (SLP-2lox/wt) and SLP-2 knockout 
(SLP-2lox/lox/Cre) mouse forebrains. Representative confocal images of Cresyl-Violet-
stained coronal hemi-sections (40µm) through cerebral cortex at different rostral 
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SLP-2 knockout  (d and e) rostral forebrains. (c) and (f) are magnified images of sections 
outlined in (b) and (e) respectively. CP: caudate putamen; LV: left ventricle; RV: right 
ventricle; Sep: septum. Scale bars: 1mm.
46
Figure 6. SLP-2 deficient primary cortical neurons survive at a level comparable to 
wild-type primary cortical neurons under normal cell culture conditions. A Live/
Dead Assay  was employed to calculate the percentage of dead cells (% Cell Death) 
relative to the total number of cells in wild-type (SLP-2lox/wt) and knockout (SLP-2lox/lox/
Cre) E14 primary cortical neuronal cultures on days 3, 5, and 7 in culture. Values 
expressed as mean ± SE for n=5 per group, P> 0.05.
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Figure 11. Cell survival under basal culture conditions. Live/Dead Assay was employed to obtain data for the 
ercentage (%) of apoptosis in wild-type (SLP-2lox/wt) and knockout (SLP-2lox/lox/Cre) E14 primary cortical 
neurons on days 3, 5, and 7 in culture. Values expressed as mean ± SED for n=5 per group, P> 0.05.
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Figure 11. Cell survival under basal culture conditions. Live/Dead Assay was employed to obtain data for the 
percentage (%) of apoptosis in wild-type (SLP-2lox/wt) and knockout (SLP-2lox/lox/Cre) E14 primary cortical 
neurons on days 3, 5, and 7 in culture. Values expressed as mean ± SED for n=5 per group, P> 0.05.
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Figure 7. SLP-2 deficient primary cortical neurons demonstrate neuritic outgrowth. 
Representative fluorescence images (600X) of (a) wild-type (SLP-2lox/wt) and (b) SLP-2 
knockout (SLP-2lox/lox/Cre) primary cortical neurons fixed on day  5 in culture.  Cells were 
labeled with an antibody against  microtubule-associated protein 2 (anti-MAP2, green) to 
detect dendrites and Hoechst 33258 (blue) to detect nuclei. Both (a) wild-type (b) SLP-2 
knockout primary  cortical neurons are MAP2-positive and display dendritic development. 
Scale bars: 20µM.
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Figure 12. Neuritic outgrowth in primary cortical neurons. Representative fluorescence images (600X) of (a) 
wild-type (SLP-2lox/wt) and (b) SLP-2 knockout (SLP-2lox/lox/Cre) primary cortical neurons fixed on day 5 in culture.  
Cells were labeled with an antibody against microtubule-associated protein 2 (anti-MAP2, green) to detect dendrites 
and H echst 33258 (blue) to detect nuclei. Both (a) wild-type (b) SLP-2 knockout primary cortical neurons are 
MAP2-positive and display dendritic development and synapse formation.
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Figure 12. Neuritic outgrowth in pri ry cortical neurons. Representative fluor scence images (600X) of (a) 
wild-type (SLP-2lox/wt) and (b) SLP-2 knockout (SLP-2lox/lox/Cre) primary cortical neurons fixed on day 5 in culture.  
Cells were lab led with an antibody gainst microt bule-associated protein 2 (anti-MAP2, green) to detect endrites 
and Hoechst 3258 (blue) to detect nuclei. Both (a) wild-type (b) SLP-2 knockout primary cortical neurons are 
MAP2-positive and display dendritic development and synapse formation.
3.2.4   Analysis of mitochondrial mass - Mitotracker Red fluorescence 
Mitochondrial dysfunction can have a number of severe cellular consequences that are 
closely linked with neurological disorders.  Through mitochondrial biogenesis, however, 
cells may increase their mitochondrial mass in an effort to counteract a decline in 
mitochondrial function, or in response to various cellular stresses, as is seen in the case of 
SIMH.  Given that SLP-2 has an implicated role in stabilizing mitochondrial fusion 
proteins, most notably during the mitochondrial stress-response (SIMH) (Szabadkai et al., 
2004; Da Cruz et al., 2010; Tondera et al., 2009; Rambold et al., 2011), we sought to 
investigate the effect of SLP-2 deficiency on mitochondrial mass in primary cortical 
neurons.
Mitotracker (MtrkR) is a red fluorescent membrane-dependent probe for staining 
mitochondria in live cells, and a useful tool for studying the mitochondrial mass within a 
given cell or cell population.  To determine whether SLP-2 deficiency has an effect on 
mitochondrial mass or membrane potential, the level of MtrkR fluorescence in both 
SLP-2 knockout (SLP-2lox/lox/Cre) and wild-type (SLP-2lox/wt) primary cortical cell cultures 
was analyzed.  Cultures were labelled with 10nM MtrkR, harvested, washed with and 
resuspended in PBS, and subjected to fluorescence-activated cell sorting (FACS) using a 
flow cytometer (BD AccuriTM C6, Biosciences).  Mean MtrkR fluorescence (FL3-H) 
values were normalized to unstained controls within each genotype.  The analysis was 
repeated four times for each genotype and results were analyzed using an unpaired t-test.  
FACS analysis revealed a significantly decreased MtrkR fluorescence in SLP-2 knockout 
primary cortical neuronal cultures when compared to wild-type (P< 0.05, n=4) (Figure 8). 
3.2.5   Analysis of mitochondrial mass -  TOM20 protein expression
Our results obtained by flow cytometry and FACS analysis (Figure 8) indicate that there 
could be a decline in the overall mitochondrial mass in SLP-2 knockout primary cortical 
cultures.  However, given that the accumulation of MtrkR in mitochondria depends on 
mitochondrial membrane potential, a decline in the level of MtrkR fluorescence signal 
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could also be indicative of mitochondrial membrane potential depolarization.  
Translocase of outer mitochondrial membrane 20 (TOM20) is a subunit of the receptor 
complex responsible for recognition and translocation of cytosolically-produced 
mitochondrial precursor proteins.  TOM20 serves as an established marker for 
mitochondrial mass and biogenesis (Whitaker-Menezes et al., 2011).  The effect of SLP-2 
deficiency on mitochondrial mass and biogenesis was thus further assessed by analyzing 
the level of TOM20 expression in both SLP-2 knockout (SLP-2lox/lox/Cre) and wild-type 
(SLP-2lox/wt) primary cortical neurons.   
Whole cell protein lysates were prepared from SLP-2 knockout and wild-type cultures 
that had been under normal culture conditions for 5 days.   Western Blot analysis was 
employed to asses the level of TOM20 protein expression in both genotypes.  A single 
band representing TOM20 was present around 15kDa in all sample lanes.  Relative 
expression of the protein was determined by densitometry analysis of Western Blots that 
were performed for three replicates for each genotype.  Densitometry values were 
normalized to Calnexin (90kDa) control, an endoplasmic reticulum (ER) membrane 
protein, and results were analyzed with one way ANOVA and Tukey’s multiple 
comparisons test.  There was no significant difference (P> 0.05, n=5) in TOM20 protein 
levels between SLP-2 knockout and wild-type cultures under normal culture conditions 
(Figure 9).
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Figure 8. Flow Cytometry and FACS  analysis reveal decreased mean Mitotracker 
Red fluorescence (FL3-H) in SLP-2 knockout primary cortical neurons. Wild-type 
(SLP-2lox/wt) and SLP-2 knockout (SLP-2lox/lox/Cre) primary cortical neurons were labeled 
with 10nM Mitotracker Red.  Fluorescence Units are normalized to unstained controls 
within each genotype. Values expressed as mean ± SE for n = 4 per group, *p < 0.05.
51
Fl
uo
re
sc
en
ce
 U
ni
ts
(m
ea
n 
FL
3-
H
)
0
200
400
600
800
wild-type (SLP-2lox/wt)
SLP-2 knockout (SLP-2lox/lox Cre+)
*
Figure 13. Mean Mitotrac er Red fluorescence (FL3-H), following Flow C tometry and 
FACS analysis. Wild type (SLP-2lox/wt) and SLP-2 knockout (SLP-2lox/lox/Cre) primary cortical 
neurons were labeled with 10nM Mitotracker Red.  Fluorescence Units are normalized to 
unlabeled controls within each genotype. Values expressed as mean ± SED for n = 4 per group, 
*p < 0.05.
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Figure 13. Mean Mitotracker Red fluorescence (FL3-H), following Flow Cytometry and 
FACS analysis. Wild type (SLP-2lox/wt) and SLP-2 knockout (SLP-2lox/lox/Cre) primary cortical 
neurons were labeled with 10nM Mitotracker Red.  Fluorescence Units are normalized to 
unlabeled controls within each genotype. Values expressed as mean ± SED for n = 4 per group, 
*p < 0.05.
Figure 6. SLP-2 up-regulation following drug treatments. SLP-2 mRNA expression (a) and representative 
Western blot (b) for SLP-2 protein expression in wild-type (SLP-2lox/wt) and SLP-2 knockout (SLP-2lox/lox/Cre) 
primary cortical neurons.  Cells were treated on day 5 in culture, and whole cell RNA and protein lysates were 
prepared following 24 hours 100µM MPP+ or 40µM CPT treatments. (a) mRNA levels are expressed relative to 
untreated (control) cells within each genotype.  (b) Control (Ctrl) cells were untreated and Calnexin serves as 
loading control.  Values expressed as mean ± SED for n = 4 per group, *p < 0.05. 
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Figure 9. SLP-2 depletion does not have an effect on mitochondrial mass in primary 
cortical neurons under normal culture conditions. Representative Western blot (a) and 
densitometry  analysis (b) of TOM20 protein expression in wild-type (SLP-2lox/wt) and 
SLP-2 knockout (SLP-2lox/lox/Cre) primary  cortical neurons. (a) Whole cell protein lysates 
were prepared on day 5 in culture.  (b) Densitometry  values for TOM20 protein 
expression were normalized to the loading control, Calnexin.  Values are expressed as 
mean ± SE for n= 5, p > 0.05.
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Figure 14. TOM20 expression in primary cortical neurons under basal conditions and following drug 
treatments. Representative Western blot (a) and densitometry analysis (b) of TOM20 protein expression in wild-
type (SLP-2lox/wt) and SLP-2 knockout (SLP-2lox/lox/Cre) primary cortical neurons. Cells were treated on day 5 in 
culture, and whole cell protein lysates were prepared following 24 hours 100µM MPP+ or 40µM CPT 
treatments.  Control (Ctrl) cells were untreated and Calnexin served as loading control.  Values are expressed as 
mean ± SED for n = 5 per control group, n = 4 per treatment group, *p< 0.05. 
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Figure 14. TOM20 expression in primary cortical neurons under basal conditions and following drug 
treatments. R presentative Western blot (a) and densitometry analysis (b) of TOM20 protein expression in wild-
type (SLP-2lox/wt) and SLP-2 knockout (SLP-2lox/lox/Cre) primary cortical neurons. Cells were treated on day 5 in 
culture, and whole cell protein lysates were prepared following 24 hours 100µM MPP+ or 40µM CPT 
treatments.  Control (Ctrl) cells were untreated and Calnexin served as loading control.  Values are expressed as 
mean ± SED for n = 5 per control group,  = 4 per treatme t group, *p< 0.05. 
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3.2.6   Analysis of mitochondrial respiration - Proteins involved in Oxidative    
           Phosphorylation 
Mitochondrial membrane potential provides a measure of the level of ion transport, and is 
therefore a prime indicator of mitochondrial health, metabolic activity and membrane 
integrity (Acton et al., 2003).   Our analyses of MtrkR fluorescence and TOM20 protein 
expression in primary cortical neurons (Sections 3.2.4 and 3.2.5) indicate that SLP-2 
depleted neuronal mitochondria likely possess depolarized membranes.  Mitochondria 
establish and maintain membrane potential mainly through proper function of the RC and 
OXPHOS along the inner mitochondrial membrane.  This is especially important for 
neurons, as they rely heavily on OXPHOS to produce the vast majority of their cellular 
ATP.  
The effect of SLP-2 deficiency on the levels of different protein complexes of the 
mitochondrial respiratory chain was thus assessed in the neuronal cell type. Whole cell 
protein lysates were prepared from SLP-2 knockout (SLP-2lox/lox/Cre) and wild-type 
primary cortical neuronal cell cultures.  A total oxidative phosphorylation monoclonal 
antibody cocktail (MitoSciences) targeting Complex II subunit 30kDa (30kDa), Complex 
III subunit Core 2 (47kDa), Complex IV subunit I (39kDa) and ATP synthase subunit 
alpha (53kDa) as well as a separate monoclonal antibody (Abcam) for Complex I subunit 
NDUFS3 (30kDa) were used to assess, by Western Blot analysis, the protein levels of 
various subunits of RC complexes involved in oxidative phosphorylation (Figure 10a).  
Densitometry analyses of Western Blots were performed for 5-7 replicates of each 
respiratory complex for primary cortical neurons of both genotypes.  Densitometry values 
were normalized to Calnexin (90kDa) control, and results were analyzed using unpaired t 
tests.  There was a significant decrease (Complex I, P< 0.05, n=5; Complex II, P < 0.05, 
n=7; Complex III, P< 0.05, n= 7; Complex IV, P< 0.05, n=7; Complex V, P< 0.05, n=6)  
in protein levels of all five subunits of complexes of the respiratory chain examined in 
SLP-2 knockout samples when compared to wild-type (Figure 10b-f).  
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Figure 6. SLP-2 up-regulation following drug treatments. SLP-2 mRNA expression (a) and representative 
Western blot (b) for SLP-2 protein expression in wild-type (SLP-2lox/wt) and SLP-2 knockout (SLP-2lox/lox/Cre) 
primary cortical neurons.  Cells were treated on day 5 in culture, and whole cell RNA and protein lysates were 
prepared following 24 hours 100µM MPP+ or 40µM CPT treatments. (a) mRNA levels are expressed relative to 
untreated (control) cells within each genotype.  (b) Control (Ctrl) cells were untreated and Calnexin serves as 
loading control.  Values expressed as mean ± SED for n = 4 per group, *p < 0.05. 
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Figure 6. S P-2 up-regulation followi g drug treatm nts. SLP-2 mRNA expression (a) and representative 
Western blot (b) for SLP-2 protein expression in wild-type (SLP-2lox/wt) and SLP-2 knockout (SLP-2lox/lox/Cre) 
primary cortical neurons.  Cells were treat d on day 5 in culture, and whole cell RNA and protein lysates were 
prepared following 24 hours 100µM MPP+ or 40µM CPT treatments. (a) mRNA levels are expressed relative to 
untreated (control) cells wi hin ach genotype.  (b) Control (Ctrl) cells were untreated and Calnexin serves as 
loading control.  Values expressed as mean ± SED for n = 4 per group, *p < 0.05. 
lox
/llo
x C
re
+
lox
/llo
x C
re
+
40uM CPT100uM MPP+
SLP-2
Calnexin
SL
P-
2
lo
x/
wt
SL
P-
2
lo
x/
wt
SL
P-
2
lo
x/
wt
SL
P-
2
lo
x/
wt
SL
P-
2
lo
x/
lo
x/
Cr
e
SL
P-
2
lo
x/
lo
x/
Cr
e
SL
P-
2
lo
x/
lo
x/
Cr
e
SL
P-
2
lo
x/
lo
x/
Cr
e
37
100
75
SL
P-
2l
ox
/w
t
SL
P-
2l
ox
/w
t
SL
P-
2l
ox
/w
t
SL
P-
2l
ox
/lo
x/C
re
SL
P-
2l
ox
/lo
x/C
re
SL
P-
2l
ox
/lo
x/C
re
MPP+ CPTCtrl Ctrl
Fo
ld
 C
ha
ng
e 
(in
c/
 C
tr
l) 
0
1
2
3
4
wild-type (SLP-2lox/wt)
SLP-2 knockout (SLP-2lox/lox Cre+)
Fo
ld
 C
ha
ng
e 
(in
c/
C
tr
l)
0
1
2
3
4
wild-type (SLP-2lox/wt)
SLP-2 knockout (SLP-2lox/lox Cre+)
100µM MPP+
SLP-2 mRNA
Fo
ld
 C
ha
ng
e 
(in
c/
 C
tr
l) 
0
1
2
3
4
wild-type (SLP-2lox/wt)
SLP-2 knockout (SLP-2lox/lox Cre+)
Fo
ld
 C
ha
ng
e 
(in
c/
C
tr
l)
0
1
2
3
4
wild-type (SLP-2lox/wt)
SLP-2 knockout (SLP-2lox/lox Cre+)
SLP-2 mRNA
40µM CPT
Fo
ld
 C
ha
ng
e 
(in
c/
 C
tr
l) 
0
1
2
3
4
wild-type (SLP-2lox/wt)
SLP-2 knockout (SLP-2lox/lox Cre+)
Fo
ld
 C
ha
ng
e 
(in
c/
C
tr
l)
0
1
2
3
4
wild-type (SLP-2lox/wt)
SLP-2 kn ckout (SLP-2lox/lox Cre+)
(a)
(b)
SLP-2
Calnexin
lox
/llo
x C
re
+
lox
/llo
x C
re
+
40uM CPT100uM MPP+
SLP-2
Calnexin
SL
P-
2
lo
x/
wt
SL
P-
2
lo
x/
wt
S
P-
2
lo
x/
wt
SL
P-
2
lo
x/
wt
SL
P-
2
lo
x/
lo
x/
Cr
e
SL
P-
2
lo
x/
lo
x/
Cr
e
SL
P-
2
lo
x/
lo
x/
Cr
e
SL
P-
2
lo
x/
lo
x/
Cr
e
37
100
75
* *
C IV
C II
 
alnexin
C IV
C II
 
alnexin
 I
C II
 
al exinCalnexin
Complex V
Complex III
Complex IV
Complex II
100
75
50
37
25
SL
P-
2l
ox
/w
t
SL
P-
2l
ox
/lo
x/C
re
Complex I - subunit NDUFS3
D
en
si
to
m
et
ry
 U
ni
ts
0
200
400
600
800
1000
wild-type (SLP-2lox/wt)
SLP-2 knockout (SLP-2lox/lox Cre+)
Complex II - subunit 30kDa
0
200
400
600
800
1000
1200
D
en
si
to
m
et
ry
 U
ni
ts
wild-type (SLP-2lox/wt)
SLP-2 knockout (SLP-2lox/lox Cre+)
Complex III - subunit Core 2
0
200
400
600
8
1000
1200
D
en
si
to
m
et
ry
 U
ni
ts
wild-type (SLP-2lox/wt)
SLP-2 knockout (SLP-2lox/lox Cre+)
Complex IV - subunit I
200
400
600
800
1000
D
en
si
to
m
et
ry
 U
ni
ts
wild-type (SLP-2lox/wt)
SLP-2 knockout (SLP-2lox/lox Cre+)
Complex V - subunit alpha
0
200
400
600
800
1000
1200
D
en
si
to
m
et
ry
 U
ni
ts
wildtype (SLP-2lox/wt)
SLP-2 knockout (SLP-2lox/lox Cre+)
*
*
**
*
Complex I - subunit NDUFS3
D
en
si
to
m
et
ry
 U
ni
ts
0
200
400
600
800
1000
wild-type (SLP-2lox/wt)
SLP-2 knockout (SLP-2lox/lox Cre+)
Complex II - subunit 30kDa
0
200
400
600
800
1000
1200
D
en
si
to
m
et
ry
 U
ni
ts
wild-type (SLP-2lox/wt)
SLP-2 knockout (SLP-2lox/lox Cre+)
Complex III - subunit Core 2
0
200
400
600
800
1000
12
D
en
si
to
m
et
ry
 U
ni
ts
wild-type (SLP-2lox/wt)
SLP-2 knockout (SLP-2lox/lox Cre+)
Complex IV - subunit I
0
200
400
600
800
1000
D
en
si
to
m
et
ry
 U
ni
ts
wild-type (SLP-2lox/wt)
SLP-2 knockout (SLP-2lox/lox Cre+)
Complex V - subunit alpha
0
200
400
600
800
1000
1200
D
en
si
to
m
et
ry
 U
ni
ts
wildtype (SLP-2lox/wt)
SLP-2 knockout (SLP-2lox/lox Cre+)
*
*
**
*
Complex I - subunit NDUFS3
D
en
si
to
m
et
ry
 U
ni
ts
0
200
400
600
800
1000
wild-type (SLP-2lox/wt)
SLP-2 knockout (SLP-2lox/lox Cre+)
Complex II - subunit 30kDa
0
200
400
600
800
1000
1200
D
en
si
to
m
et
ry
 U
ni
ts
wild- ype (SLP-2lox/wt)
SLP-  knockout (SLP-2l x/lox Cre+)
Complex III - subunit Core 2
0
200
400
600
800
1000
1200
D
en
si
to
m
et
ry
 U
ni
ts
wild-type (SLP-2lox/wt)
SLP-2 knockout (SLP-2lox/lox Cre+)
Complex IV - subunit I
0
200
400
6 0
800
1000
D
en
si
to
m
et
ry
 U
ni
ts
wild-type (SLP-2lox/wt)
SLP-2 knockout (SLP-2lox/lox Cre+)
Complex V - subunit alpha
0
200
400
600
800
1000
1200
D
en
si
to
m
et
ry
 U
ni
ts
wildtype (SLP-2lox/wt)
SLP-2 knockout (SLP-2lox/lox Cre+)
*
*
**
*
Complex I - subunit NDUFS3
D
en
si
to
m
et
ry
 U
ni
ts
0
200
400
600
800
1000
wild-type (SLP-2lox/wt)
SLP-2 knockout (SLP-2lox/lox Cre+)
Complex II - subunit 30kDa
0
200
400
600
800
1000
1200
D
en
si
to
m
et
ry
 U
ni
ts
wild-type (SLP-2lox/wt)
SLP-2 knockout (SLP-2lox/lox Cre+)
Complex III - subunit Core 2
0
200
400
600
800
1000
1200
D
en
si
to
m
et
ry
 U
ni
ts
wild-type (SLP-2lox/wt)
SLP-2 knockout (SLP-2lox/lox Cre+)
Complex IV - subunit I
0
200
400
600
8 0
1000
D
en
si
to
m
et
ry
 U
ni
ts
wild-type (SLP-2lox/wt)
SLP-2 knockout (SLP-2lox/lox Cre+)
Complex V - subunit alpha
0
2 0
4
6
8
1
12
D
en
si
to
m
et
ry
 U
ni
ts
wildtype (SLP-2lox/wt)
SLP-2 knockout (SLP-2lox/lox Cre+)
*
*
**
*
Comple I - subunit NDUFS3
D
en
si
to
m
et
ry
 U
ni
ts
0
200
400
600
8
1000
wild-type (SLP-2lox/wt)
SLP-2 knockout (SLP-2lox/lox Cre+)
Complex II - subunit 30kDa
0
20
4 0
6 0
8 0
1 0
12
D
en
si
to
m
et
ry
 U
ni
ts
wild-type (SLP-2lox/wt)
SLP-2 knockout (SLP-2lox/lox Cre+)
Complex III - subunit Core 2
0
200
400
600
800
1000
1200
D
en
si
to
m
et
ry
 U
ni
ts
wild-type (SLP-2lox/wt)
SLP-2 knockout (SLP-2lox/lox Cre+)
Complex IV - subunit I
0
200
400
600
800
100
D
en
si
to
m
et
ry
 U
ni
ts
wild-type (SLP-2lox/wt)
SLP-2 knockout (SLP-2lox/lox Cre+)
Complex V - subunit alpha
0
200
400
600
800
1000
1200
D
en
si
to
m
et
ry
 U
ni
ts
wildtype (SLP-2lox/wt)
SLP-2 knockout (SLP-2lox/lox Cre+)
*
*
**
*
Complex I - subunit NDUFS3
D
en
si
to
m
et
ry
 U
ni
ts
0
200
400
600
800
1000
wild-type (SLP-2lox/wt)
SLP-2 knockout (SLP-2lox/lox Cre+)
Complex II - subunit 30kDa
0
200
400
600
800
1000
1200
D
en
si
to
m
et
ry
 U
ni
ts
wild-type (SLP-2lox/wt)
SLP-2 knocko t (SLP-2lox/lox Cre+)
Complex III - subunit Core 2
0
200
400
600
800
1000
1200
D
en
si
to
m
et
ry
 U
ni
ts
wild-type (SLP-2lox/wt)
SLP-2 knockout (SLP-2lox/lox Cre+)
Complex IV - subunit I
0
200
400
600
800
1000
D
en
si
to
m
et
ry
 U
ni
ts
wild-type (SLP-2lox/wt)
SLP-2 knockout (SLP-2lox/lox Cre+)
Complex V - subunit alpha
0
200
400
600
800
1000
1200
D
en
si
to
m
et
ry
 U
ni
ts
wildtype (SLP-2lox/wt)
SLP-2 knocko t (SLP-2lox/lox Cre+)
*
*
**
*
(a)
Complex I
Calnexin
25
75
10
C IV
C II
C V
al exin
C IV
C II
C V
alnexin
 I
C II
 
aln xinCalnexin
Complex V
Complex III
Co plex IV
Complex II
100
75
50
37
25
SL
P-
2l
ox
/w
t
SL
P-
2l
ox
/lo
x/C
re
Complex I - subunit NDUFS3
D
en
si
to
m
et
ry
 U
ni
ts
0
200
400
600
800
1000
wild-type (SLP-2lox/wt)
SLP-2 knockout (SLP-2lox/lox Cre+)
Complex II - subunit 30kDa
0
200
400
600
800
1000
1200
D
en
si
to
m
et
ry
 U
ni
ts
wild-type (SLP-2lox/wt)
SLP-2 knockout (SLP-2lox/lox Cre+)
Complex III - subunit Core 2
0
20
400
600
800
1000
12
D
en
si
to
m
et
ry
 U
ni
ts
wild-type (SLP-2lox/wt)
SLP-2 knockout (SLP-2lox/lox Cre+)
Complex IV - subunit I
0
200
400
600
800
1000
D
en
si
to
m
et
ry
 U
ni
ts
wild-type (SLP-2lox/wt)
SLP-2 knockout (SLP-2lox/lox Cre+)
Complex V - subunit alpha
0
200
400
600
800
1000
1200
D
en
si
to
m
et
ry
 U
ni
ts
wildtype (SLP-2lox/wt)
SLP-2 knockout (SLP-2lox/lox Cre+)
*
*
**
*
Complex I - subunit NDUFS3
D
en
si
to
m
et
ry
 U
ni
ts
0
200
400
600
800
1000
wild-type (SLP-2lox/wt)
SLP-2 knockout (SLP-2lox/lox Cre+)
l II - it 30kDa
0
200
400
600
8 0
1000
1200
D
en
si
to
m
et
ry
 U
ni
ts
wild-type (SLP-2lox/wt)
SLP-2 knockout (SLP-2lox/l x Cre+)
Complex III - subunit Core 2
0
200
400
60
80
100
12
D
en
si
to
m
et
ry
 U
ni
ts
wild-type (SLP-2lox/wt)
SLP-2 knockout (SLP-2lox/lox Cre+)
Complex IV - subunit I
0
200
400
600
800
1000
D
en
si
to
m
et
ry
 U
ni
ts
wild-type (SLP-2lox/wt)
SLP-2 knockout (SLP-2lox/lox Cre+)
Comple  V - subunit alpha
0
200
400
600
800
1000
1200
D
en
si
to
m
et
ry
 U
ni
ts
wildtype (SLP-2lox/wt)
SLP-2 knoc out (SLP-2lox/lox Cre+)
*
*
**
*
Complex I - subunit NDUFS3
D
en
si
to
m
et
ry
 U
ni
ts
0
200
400
600
800
1000
wild-type (SLP-2lox/wt)
SLP-2 knockout (SLP-2lox/lox Cre+)
Complex II - subunit 30kDa
0
200
400
600
800
1000
1200
D
en
si
to
m
et
ry
 U
ni
ts
wild-type (SLP-2lox/wt)
SLP-2 kn ckout (SLP-2lox/lo  Cre+)
Complex III - subunit Core 2
0
200
400
600
800
1000
1200
D
en
si
to
m
et
ry
 U
ni
ts
wild-type (SLP-2lox/wt)
SLP-2 knockout (SLP-2lox/lox Cre )
Complex IV - subunit I
0
200
400
600
800
1000
D
en
si
to
m
et
ry
 U
ni
ts
wild-type (SLP-2lox/wt)
SLP-2 knockout (SLP-2lox/lox Cre+)
Complex V - subunit alpha
0
200
400
600
800
1000
1200
D
en
si
to
m
et
ry
 U
ni
ts
wildtype (SLP-2lox/w )
SLP-2 knockout (SLP-2lox/lox Cre+)
*
*
**
*
Complex I - subunit NDUFS3
D
en
si
to
m
et
ry
 U
ni
ts
0
200
400
600
800
1000
wild-type ( - lox/wt)
SLP-2 knockout (SLP-2lox/lox Cre+)
Complex II - subunit 30kDa
0
200
400
600
800
1000
1200
D
en
si
to
m
et
ry
 U
ni
ts
wild-type (SLP-2lox/wt)
SLP-2 kn ckout (SLP-2lox/lox Cre+)
Complex III - subunit Core 2
0
200
400
600
800
1000
1200
D
en
si
to
m
et
ry
 U
ni
ts
wild-type (SLP-2lox/wt)
SLP-2 knockout (SLP-2lo /lox Cre+)
Complex IV - subunit I
0
2
40
600
1000
D
en
si
to
m
et
ry
 U
ni
ts
wild- ype (SLP-2lox/wt
SLP-2 knockout (SLP-2lox/lox Cre+)
Complex V - subunit alpha
0
20
4
6
8
10
2
D
en
si
to
m
et
ry
 U
ni
ts
wildtype (SLP-2lox/wt)
SLP-2 knockout (SLP-2lox/lox Cre+)
*
*
**
*
o plex I - su it NDUFS3
D
en
si
to
m
et
ry
 U
ni
ts
0
200
400
600
8
1000
wild-type (SLP-2lox/wt)
SLP-2 knockout (SLP-2lox/lox Cre+)
Complex II - subunit 30kDa
0
20
400
600
800
10
1200
D
en
si
to
m
et
ry
 U
ni
ts
wild-type (SLP-2lox/wt)
SLP-2 knockout (SLP-2lox/lox Cre+)
C mplex III - subunit Core 2
0
200
4 0
6
8
1
12
D
en
si
to
m
et
ry
 U
ni
ts
wild-type (SLP-2lox/wt)
SLP-2 knockout (SLP-2lox/lox Cre+)
C mplex IV - subunit I
0
200
400
6 0
800
1000
D
en
si
to
m
et
ry
 U
ni
ts
wild-type (SLP-2lox/wt)
SLP-2 knockout (SLP-2lox/lox Cre+)
Comp ex V - subunit alpha
0
200
400
600
800
1000
1200
D
en
si
to
m
et
ry
 U
ni
ts
wildtype (SLP-2lox/wt)
SLP-2 knockout (SLP-2lox/lox Cre+)
*
*
**
*
Complex I - subunit NDUFS3
D
en
si
to
m
et
ry
 U
ni
ts
0
20
4
6
8
10
wild-type (SLP-2lox/wt)
SLP-2 knockout (SLP-2lox/lox Cre+)
Complex II - subunit 30kDa
0
200
400
600
800
1000
1200
D
en
si
to
m
et
ry
 U
ni
ts
wild-type (SLP-2lox/wt)
SLP-2 knockout (SLP-2lox/lox Cre+)
Complex III - subunit Core 2
0
200
400
600
800
1000
1200
D
en
si
to
m
et
ry
 U
ni
ts
wild-type (SLP-2lox/wt)
SLP-2 knockout (SLP-2lox/lox Cre+)
Complex IV - subunit I
0
200
40
60
80
100
D
en
si
to
m
et
ry
 U
ni
ts
wild-type (SLP-2lox/wt)
SLP-2 knockout (SLP-2lox/lox Cre+)
Complex V - subunit alpha
0
200
400
600
800
1000
1200
D
en
si
to
m
et
ry
 U
ni
ts
wildtype (SLP-2lox/wt)
SLP-2 knockout (SLP-2lox/lox Cre+)
*
*
**
*
(a)
Complex I
Calnexin
25
75
1 0
Figure 6. SLP-2 up-regulation following drug treatments. SLP-2 mRNA expression (a) and representative 
Western blot (b) for SLP-2 protein expression in wild-type (SLP-2lox/wt) and SLP-2 knockout (SLP-2lox/lox/Cre) 
primary cortical neurons.  Cells were treated on day 5 in culture, and whole cell RNA and protein lysates were 
prepared following 24 hours 100µM MPP+ or 40µM CPT treatments. (a) mRNA levels are expressed relative to 
untreated (control) cells within each genotype.  (b) Control (Ctrl) cells were untreated and Calnexin serves as 
loading control.  Values expressed as mean ± SED for n = 4 per group, *p < 0.05. 
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Figure 6. SL -  up-regulation f llowing d ug tr a ments. SLP-2 mRNA expression (a) and representative 
Western blot (b) for SLP-2 protein expression in wild-type (SLP-2lox/wt) and SLP-2 knockout (SLP-2lox/lox/Cre) 
primary co tic l neurons.  Cells were treated on day 5 in culture, and whole cell RNA and protein lysates were 
prepared following 24 hours 100µM MPP+ or 40µM CPT treatments. (a) mRNA levels are expressed relative to 
untreated (contro ) cells within each genotyp .  (b) Control (Ctrl) cells were untreated and Calnexin serves as 
l ading control.  Values expressed as mean ± SED for n = 4 per group, *p < 0.05. 
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Fig re 6. SLP-2 up-regulation following drug treatments. SLP-2 mRNA expression (a) and representative 
Western blot (b) for SLP-2 protein expression in wild-type (SLP-2lox/wt) and SLP-2 knockout (SLP-2lox/lox/Cre) 
primary cortical neurons.  Cells were treated on day 5 in culture, and whole cell RNA and protein lysates were 
prepa ed following 24 hours 100µM MPP+ or 40µM CPT treatments. (a) mRNA levels are expressed relative to 
untreated (control) cells within each genotype.  (b) Control (Ctrl) cells were untreated and Calnexin serves as 
loading c ntrol.  Values expressed as mean ± SED for n = 4 per group, *p < 0.05. 
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Figure 10. Depletion of SLP-2 is associated with de reased OXPHOS pr tein levels 
in pri ary cortical neurons. Representative W stern blot (a) and densitometry  (b-f) 
analysis for Complex I (subu it NDUF 3), Complex II (subunit 30kDa), Complex III 
(subunit Core 2), Comple  IV (subunit I), and Complex V (subunit alpha) of the electron 
transport chain in wild-type (SLP-2lox/wt) and SLP-2 knockout (SLP-2lox/lox/Cre) primary 
cortical neurons.  Whole cell protein lysates were prepared on day 5 in culture. 
Densitometry values are normalized to the loading control, Calnexin. Values are 
expresse  as mean ± SE for n= 5-7, *p< 0.05.
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3.3   Examining the role of SLP-2 in neuronal mitochondria under various
        conditions of stress
3.3.1   SLP-2 up-regulation in response to oxidative stress and DNA damage
We have identified SLP-2 as a stress-inducible transcript in a previous microarray study 
employing a variety of stressors (unpublished data).  We therefore sought to further 
characterize the stress-responsive expression pattern of SLP-2 in primary cortical 
neurons, by examining its expression specifically in response to drug-induced oxidative 
stress and DNA damage. The mitochondrial stressor MPP+ is a Complex I (NADH 
dehydrogenase) inhibitor that can mimic the symptoms of PD when administered to 
rodents or primates (Braungart et al., 2004; Sherer et al., 2003).  MPP+ functions to 
interfere with oxidative phosphorylation in mitochondria, resulting in oxidative stress, 
depletion of ATP and cell death.  Camptothecin (CPT), on the other hand, is a class I 
DNA topoisomerase inhibitor that promotes DNA breakage, and induces a host of cellular 
activities that ultimately lead to apoptosis (Sen et al., 2004).
Whole cell RNA and protein lysates were prepared from both SLP-2 knockout (SLP-2lox/
lox/Cre) and wild-type (SLP-2lox/wt) primary cortical neurons following 24 hours treatment 
with either 100µM MPP+ or 40µM CPT.  qRT-PCR and Western blot analysis were 
employed to analyze changes in SLP-2 mRNA and protein levels respectively.
Expression levels of SLP-2 mRNA were determined by qRT-PCR, and changes in 
mRNA expression levels were calculated as fold change expressed relative to an 
untreated control within each genotype, using the delta-delta CT method.  The analysis 
was repeated four times for each genotype (SLP-2 knockout data not shown) following 
each treatment, and results were analyzed using unpaired t-tests.  There was a ~3-fold 
increase in SLP-2 mRNA levels following both MPP+ and CPT treatments in wild-type 
cortical neurons (Figure 11a).
Western blot and subsequent densitometry analysis was used to compare the level of 
SLP-2 protein expression following MPP+ and CPT treatments.  The analyses were 
55
repeated three times for each genotype following each treatment and results were 
analyzed using a one-way ANOVA and Tukey’s multiple comparisons test.  There was a 
significantly increased level of SLP-2 protein expression in wild-type cultures following 
both MPP+ and CPT treatments (P<0.05, n=3) and as expected, SLP-2 could not be 
detected in extracts from SLP-2 knockout cultures (Figure 11b). 
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Figure 6. SLP-2 up-regulation following drug treatments. SLP-2 mRNA expression (a) and representative 
Western blot (b) for SLP-2 protein expression in wild-type (SLP-2lox/wt) and SLP-2 knockout (SLP-2lox/lox/Cre) 
primary cortical neurons.  Cells were treated on day 5 in culture, and whole cell RNA and protein lysates were 
prepared following 24 hours 100µM MPP+ or 40µM CPT treatments. (a) mRNA levels are expressed relative to 
untreated (control) cells within each genotype.  (b) Control (Ctrl) cells were untreated and Calnexin serves as 
loading control.  Values expressed as mean ± SED for n = 4 per group, *p < 0.05. 
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Figure 11. SLP-2 expression is up-regulated in primary cortical neurons in response 
to oxidative stress and DNA damage. SLP-2 mRNA expression (a) and representative 
Western blot and densitometry analysis (b) for SLP-2 protein expression in wild-type 
(SLP-2lox/wt) and SLP-2 knockout (SLP-2lox/lox/Cre) primary cortical neurons. 
Densitometry analysis was only preformed for cells expressing SLP-2 (SLP-2lox/wt).  Cells 
were treated on day 5 in culture, and whole cell RNA and protein lysates were prepared 
following 24 hours 100µM MPP+ or 40µM  CPT treatments. (a) mRNA levels are 
expressed relative to untreated (control) cells within each genotype.  (b) Control (Ctrl) 
cells were untreated and (c) densitometry  values were normalized to the loading control, 
Calnexin.  Values expressed as mean ± SE for (a) n = 4 per group, and (b) n=3 per group, 
*p< 0.05.
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3.3.2   Analysis of mitochondrial biogenesis in response to oxidative stress and
          DNA damage
When cells are exposed to selective stresses, they may undergo SIMH.  As mentioned 
(Section 1.2.1), this process involves increased mitochondrial biogenesis and ATP 
production, and confers on cells a resistance to stress (Tondera et al., 2009; Rambold et 
al., 2011).  SLP-2 is required to stabilize the fusion mediator L-OPA1 during SIMH 
(Szabadkai et al., 2004; Da Cruz et al., 2010; Tondera et al., 2009; Rambold et al., 2011).  
Given that our results indicate that SLP-2 expression is induced in response to both 
MPP+ and CPT treatments (Section 3.3.1, Figure 11), we sought to gain further insight 
into the role of SLP-2 in mitochondrial biogenesis, by examining the effects of these 
same treatments on mitochondrial mass in the neuronal cell type, both in the presence and 
absence of SLP-2.  
The level of TOM20 protein expression is a suitable measure of mitochondrial mass and 
biogenesis, as previously described (see Section 3.3.5) for experiments conducted in 
primary cortical neurons under normal culture conditions.  Thus, the effect of SLP-2 
deficiency on mitochondrial mass and biogenesis was further assessed by analyzing the 
level of TOM20 expression in both SLP-2 knockout (SLP-2lox/lox/Cre) and wild-type 
(SLP-2lox/wt) primary cortical neurons following 24 hours treatment with either a 
mitochondrial stressor (MPP+) or DNA-damaging agent (CPT).  
Whole cell protein lysates were prepared from SLP-2 knockout and wild-type cultures 
under normal culture conditions and following 24 hours treatment with either 100µM 
MPP+ or 40µM CPT.  Relative expression of TOM20 protein was determined by 
densitometry analysis of Western Blots that were performed for three replicates for each 
genotype and drug treatment.  Densitometry values were normalized to Calnexin (90kDa) 
control, and results were analyzed with one way ANOVA and Tukey’s multiple 
comparisons test.
Similar to the data obtained from analysis of TOM20 expression under normal culture 
conditions (Figure 9), there was no significant difference (P> 0.05, n=5) in TOM20 
58
protein levels between SLP-2 knockout and wild-type cultures following either MPP+ or 
CPT treatments (Figure 12).  There was a significant increase in TOM20 expression 
following both MPP+ and CPT treatments within each genotype (P<0.05, n= 3 for MPP+, 
n= 4 for CPT).
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(a)
(b)
Figure 12. SLP-2 depletion does not have an effect on mitochondrial mass in 
primary cortical neurons following stressful stimuli.  Representative Western blot (a) 
and densitometry analysis (b) of TOM20 protein expression in wild-type (SLP-2lox/wt) and 
SLP-2 knockout (SLP-2lox/lox/Cre) primary cortical neurons. Cells were treated on day 5 in 
culture, and whole cell protein lysates were prepared following 24 hours 100µM  MPP+ 
or 40µM CPT treatments.  Control (Ctrl) cells were untreated and densitometry values 
were normalized to the loading control, Calnexin.  Values are expressed as mean ± SE for 
n= 5 per control group, p > 0.05; n= 3-4 per treatment group, p > 0.05.
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Figure 14. TOM20 expression in primary cortical neurons under basal conditions and following drug 
treatments. Representative Western blot (a) and densitometry analysis (b) of TOM20 protein expression in wild-
type (SLP-2lox/wt) and SLP-2 knockout (SLP-2lox/lox/Cre) primary cortical neurons. Cells were treated on day 5 in 
culture, and whole cell protein lysates were prepared following 24 h urs 100µM MPP+ or 40µM CPT 
treatments.  Contr l (Ctrl) cells were untreated and Calnexin served as loading control.  Values are expressed as 
mean ± SED for n = 5 per control group, n = 4 per treatment group, *p< 0.05. 
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Figure 14. TOM20 expression in primary cortical neurons under basal conditions and following drug 
treatments. Representative Western blot (a) and densitometry analysis (b) of TOM20 protein expression in wild-
type (SLP-2lox/wt) and SLP-  knockout (SLP-2lox/lox/Cre) primary c rtical neurons. Cells were treated on day 5 in 
c lt re, and whole cell protein lysates were prepared following 24 hours 100µM MPP+ or 4  CPT 
treatments.  Control (Ctrl) cells were untreated and Calnexin served as loading control.  Values are expressed as 
mean ± SED for n = 6 per control group, p > 0.05; n = 3 per treatment group, p > 0.05. 
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Figure 6. SLP-2 up-regulation following drug treatments. SLP-2 mRNA expression (a) and representative 
Western blot (b) for SLP-2 protein expression in wild-type (SLP-2lox/wt) and SLP-2 knockout (SLP-2lox/lox/Cre) 
primary cortical neurons.  Cells were treated on day 5 in culture, and whole cell RNA and protein lysates were 
prepared following 24 hours 100µM MPP+ or 40µM CPT treatments. (a) mRNA levels are expressed relative to 
untreated (control) cells within each genotype.  (b) Control (Ctrl) cells were untreated and Calnexin serves as 
loading control.  Values expressed as mean ± SED for n = 4 per group, *p < 0.05. 
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3.3.3   Analysis of PGC-1α mRNA expression following oxidative stress and DNA
           damage
PGC-1α is a master co-activator and regulator of mitochondrial biogenesis and energy 
expenditure (Ciron et al., 2012; Hempenstall et al., 2012; Puigserver et al., 2003), found 
up-regulated under conditions of increased cellular energy demand, such as in response to 
gluconeogenesis, thermogenesis, and exercise (Christie et al., 2011; Yoon et al., 2001).  
Additionally, PGC-1α regulates the activity of a number of transcription factors involved 
in a number of metabolic pathways.   This includes downstream induction of replication 
of the mitochondrial genome, resulting in stimulation of mitochondrial biogenesis and 
respiration (Scarpulla et al., 2008; Hempenstall et al., 2012; Puigserver et al., 2003).  
Our results indicate that both oxidative stress (MPP+) and DNA damage (CPT) result in 
increased mitochondrial biogenesis in neurons, as demonstrated by an increase in 
mitochondrial mass (Figure 12).  Previous studies have implicated a role for SLP-2 in 
SIMH in a number of non-neuronal mammalian cell-lines and mouse cell types (Tondera 
et al., 2009; Christie et al., 2011).  In this study, we have shown that there is an increase 
in SLP-2 expression in neurons, in response to stress induced by both oxidative stress and 
DNA damage (Figure 11).  Interestingly, our data further illustrates that SLP-2 is not 
required for the induction of mitochondrial biogenesis in neurons, in response to stress 
induced by MPP+ or CPT (Figure 12).  Previous studies examining the role of SLP-2 
during T-Cell activation have shown that SLP-2 up-regulation precedes PGC-1α up-
regulation and mitochondrial biogenesis (Christie et al., 2011).  In an effort to further 
characterize the stress-induced up-regulation of SLP-2, and gain further insight into the 
mechanism by which a concomitant increase in mitochondrial mass occurs, we sought to 
determine whether SLP-2 may induce the transcription of mitochondrial target genes in 
neurons.  We therefore examined the expression of PGC-1α in primary cortical neurons 
following treatment with MPP+ and CPT.
Total RNA was extracted from both SLP-2 knockout (SLP-2lox/lox/Cre) and wild-type 
(SLP-2lox/wt) primary cortical neurons treated with either 100µM MPP+ or 40µM CPT for 
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24 hours.  Expression levels of PGC-1α mRNA were determined by qRT-PCR, and 
changes in mRNA expression levels were calculated as fold change expressed relative to 
an untreated control within each genotype, using the delta-delta CT method.  The analysis 
was repeated five times for wild type cultures and four times for SLP-2 knockout cultures 
and results were analyzed using an unpaired t-test.  Following CPT treatment, there was 
significantly greater fold increase in PGC-1α mRNA expression (P<0.05, n=4) in SLP-2 
knockout cultures relative to wild-type cultures  There was no significant difference (P> 
0.05, n=4) in PGC-1α mRNA levels between SLP-2 knockout and control cultures 
following MPP+ treatment (Figure 13).
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Figure 13. PGC-1α is up-regulated in primary cortical  neurons in response to DNA 
damage.  PGC-1α mRNA expression in wild-type (SLP-2lox/wt) and SLP-2 knockout 
(SLP-2lox/lox/Cre) primary  cortical neurons was measured by qRT-PCR.  Cells were treated 
on day 5 in culture, and whole cell RNA lysates were prepared following 24 hours 
100µM MPP+ or  40µM  CPT treatments.  mRNA levels are expressed relative to 
untreated (control) cells within each genotype.  Values expressed as mean ± SE for n = 4 
per group, *p < 0.05. 
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Figure 7. PGC-1α up-regulation following drug treatments.  PGC-1α mRNA expression in wild-
type (SLP-2lox/wt) and SLP-2 knockout (SLP-2lox/lox/Cre) primary cortical neurons.  Cells were treated on 
day 5 in culture, and whole cell RNA lysates were prepared following 24 hours 100µM MPP+ or  
40µM CPT treatments.  mRNA lev ls are expressed relative to untreat d (control) cells within each 
genotype.  Values expressed as mean ± SED for n = 4 per group, *p < 0.05   
PGC-1α up-regulation following drug treatments.  PGC-1α mRNA expression in wild-type 
(SLP-2lox/wt) and SLP-2 knockout (SLP-2lox/lox/Cre) primary cortical neurons.  Cells were treated on day 
5 in culture, and whole cell RNA lysates were prepared following 24 hours 100µM MPP+ or 40µM 
CPT treatments. (a) mRNA levels are expressed relative to untreated (control) cells within each 
genotype.  
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3.3.4    Analysis of the effects of SLP-2-depletion on neuron survival following
            oxidative stress and DNA damage
Our results indicate that SLP-2 knockout primary cortical neurons survive under normal 
cell culture conditions at a level that is comparable to wild-type primary cortical neurons 
(Figure 6).  Additionally, we have shown that SLP-2 is up-regulated in primary cortical 
neurons in response to both oxidative stress and DNA damage (Figure 11).  In an effort to 
determine whether up-regulation of SLP-2 occurs as a pro-survival response in neurons, 
and further characterize the role of SLP-2 in the neuronal stress-response, we sought to 
examine the effects of SLP-2 depletion on neuronal cell survival in response to a number 
of cell stressors.
In addition to MPP+ and CPT, we employed 3-NP in our experiments, as a secondary 
model of mitochondrial inhibition and oxidative stress.  3-NP is a complex II (succinate 
dehydrogenase) inhibitor and has been previously used to produce animal models of 
Huntington’s Disease (Huang et al., 2006; Beal et al., 1993; Borlongan et al., 1997).
Following 24 hour treatments with 100µM MPP+, 10µM 3-NP, or 40µM CPT, the 
percentage of cell death in both SLP-2 knockout (SLP-2lox/lox/Cre) and wild-type 
(SLP-2lox/wt) primary cortical cultures was assessed using a Live/Dead Assay 
(Invitrogen).  The analysis was repeated six times for each genotype following each drug 
treatment, and results were analyzed using a one-way ANOVA and Tukey’s multiple 
comparisons test.  Following treatment with mitochondrial stressors, MPP+ and 3-NP, a 
significantly lower percentage of cell death (P< 0.05, n=6) was observed in SLP-2 
knockout cultures relative to wild-type cultures (Figure 14a and 14b).  Conversely, 
following treatment with a DNA-damaging agent, CPT, a significantly greater percentage 
of cell death (P< 0.05, n=6) was observed in SLP-2 knockout cultures relative to wild-
type cultures (Figure 14c).
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Figure 14. SLP-2 depletion has a differential effect on survival in primary cortical 
neurons in response to oxidative stress and DNA damage.  A Live/Dead Assay was 
employed to calculate the percentage of dead cells (% Cell Death) relative to the total 
number of c lls following 24 hours treatment with a) 10  MPP+, b) 10µM 3-N , and 
c) 40µM  CPT. Both wild-t pe (SLP-2lox/wt) and knockout (SLP-2lox/lox/Cre) primary 
cortical cultures were treated on day 5 in culture. Control (Ctrl) cells were untreated. 
Values expressed as mean ± SED for n=6 per group, *p < 0.05.
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3.3.5    Analysis of the effects of SLP-2 induction on neuron survival following  
            oxidative stress and DNA damage 
Our results indicate that SLP-2 is up-regulated in primary cortical neurons in response to 
both oxidative stress and DNA damage (Figure 11).  SLP-2 depletion, however, appears 
to have a differential effect on cell survival in response to both of these stresses (Figure 
14).  In an effort to further characterize the potentially pro-survival induction of SLP-2 
expression in neurons in response to stressful stimuli (MPP+, 3-NP, CPT), we sought to 
examine whether preemptive over-expression of SLP-2 would have a protective effect in 
neurons exposed to similar stresses. 
We therefore adopted an SN56 neuronal cell line to study the effects of enforced 
expression of SLP-2 on cell survival. When differentiated, SN56 cells possess neuronal 
morphology and a cholinergic phenotype (Krieglstein et al., 2008).  Serum withdrawal 
was employed to induce differentiation in SN56 cells.  Subsequently, either GFP plasmid 
(pEGFP) or SLP-2-GFP plasmid (pSLP-2-GFP), was transfected into SN56 cell cultures, 
using a calcium phosphate transfection method as outlined in section 2.2.4.   Whole cell 
protein lysates were extracted from SN56 cells following expression of SLP-2-GFP or 
EGFP in cultures demonstrating 30-40% transfection efficiency.  The relative expression 
levels of SLP-2 protein in transfected SN56 cell cultures were examined by Western Blot 
analysis, which revealed increased SLP-2 protein levels in SN56 cultures transfected with 
pSLP-2-GFP when compared to those that were un-transfected or transfected with 
pEGFP (Figure 15a).  
SN56 cells transfected with pSLP-2-GFP display a punctate and cytoplasmic GFP signal 
that appears to co-localize with the mitochondrial mass (Figure 15b, top panels).  
Conversely, SN56 cells transfected with pEGFP display a diffuse GFP signal throughout 
the cytoplasm and nucleus (Figure 15b, bottom panels).
Due to the highly proliferative and metabolically active nature of the SN56 cell line, a 
dose-responsive range for treatment with 3-NP was not attainable (data not shown).  
Following 24 hours treatment with 5µM and 50µM MPP+, and 40µM CPT, however, the 
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percentage of apoptotic cells in cultures of differentiated SN56 cells expressing either 
EGFP or SLP-2-GFP was assessed using Hoechst 33342 staining to visualize apoptotic 
nuclei.  A representative fluorescence image of Hoechst 33342 staining used to 
distinguish characteristic apoptotic nuclei is included in Appendix D.  
The analysis was repeated four times for each plasmid following each drug treatment, and 
results were analyzed using a one-way ANOVA and Tukey’s multiple comparisons test.  
Following treatment with mitochondrial stressor MPP+, a significantly greater percentage 
of apoptosis (P< 0.05, n=4) was observed in cells expressing SLP-2-GFP relative to those 
expressing EGFP (Figure 16a).  Conversely, following treatment with the DNA-
damaging agent, CPT, a significantly lower percentage of apoptosis (P< 0.05, n=4) was 
observed in cells over-expressing pSLP-2-GFP relative to cells over-expressing pEGFP 
(Figure 16b).
3.3.6    Analysis of mitochondrial respiration - Proteins involved in Oxidative 
            Phosphorylation
Our results indicate that SLP-2 depletion has a significant effect on the protein levels of  
subunits from all five complexes of the mitochondrial respiratory chain (Figure 10).  We 
therefore sought to further characterize the role of SLP-2 in stabilizing mitochondrial 
OXPHOS proteins by employing our model of enforced SLP-2 expression in SN56 cells, 
to examine whether SLP-2 up-regulation, in neurons, was associated with changes in 
protein levels of subunits of RC complexes involved in mitochondrial respiration.
Whole cell protein lysates were prepared from SN56 cells transfected with either pEGFP 
or pSLP-2-GFP.  Similar to our previous experiments in primary cortical neurons 
(Section 3.2.6), a total oxidative phosphorylation monoclonal antibody cocktail 
(MitoSciences) and a separate monoclonal antibody for Complex I subunit NDUFS3 
(Abcam) were used to detect, by Western Blot analysis, levels of specific proteins 
involved in oxidative phosphorylation (Figure 17a).  Densitometry analysis of Western 
Blots was performed for 3 replicates for SN56 cells for both transfected plasmids.  
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Densitometry values were normalized to Calnexin (90kDa) control, and results were 
analyzed using unpaired t tests.  There was a significant increase in Complex I NDUFS3 
subunit protein levels (P<0.05, n=3) in SN56 cells over-expressing SLP-2GFP relative to 
those over expressing EGFP.  There was no significant difference in protein levels for 
subunits of complexes II-V in SN56 cells expressing SLP-2-GFP relative to those 
expressing EGFP (Figure 17b-f).
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Figure 5. Confirmation of SLP-2-GFP plasmid expression. (a) Representative Western blot analysis showing pSLP-2-GFP 
plasmid expression in differentiated SN56 cells. Whole cell protein lysates were prepared following differentiation induced by 
serum-withdrawal, and transfection by a calcium phosphate method.  Calnexin serves as loading control. (b) Representative 
fluorescence images (600X) showing co-localization (yellow) of SLP-2-GFP and mitochondria in SN56 cells transfected with 
SLP-2-GFP plasmid (pSLP-2GFP, top panels). SN56 cells transfected with GFP plasmid (pEGFP, bottom panels) display a 
diffuse GFP signal.  Hoechst 33258 (blue), a nuclear marker, is shown in the first panel; TOM20 (red), a mitochondrial 
marker, is shown in the second panel; GFP (green), plasmid protein expression marker, is shown in the third panel; and the 
fourth panel shows the first three panels merged together.  
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Figure 15. Confirmation of SLP-2-GFP expression. (a) Representative Western blot 
analysis of pSLP-2-GFP plasmid expression in differentiated SN56 cells. Whole cell 
pr tein lysates were prepared f llowing differentiation induced by serum-withdraw l, and 
transfection by  a calcium phosphate method.  Calnexin serves as loading control. (b) 
Representative fluorescence images showing co-localization (yellow) of SLP-2-GFP and 
mitochondria in SN56 cell  transfected with SLP-2-GFP plasmid (pSLP-2GFP, top 
panels). SN56 cells transfected with GFP plasmid (pEGFP, bottom panels) display a 
diffuse GFP signal.  Hoechst 33258 (blue), a nuclear marker, is shown in the first panel; 
TOM20 (red), a mitochondrial marker, is shown in the second panel; GFP (green), 
plasmid protein expression marker, is shown in the third panel; and the fourth panel 
shows the first three panels merged together. Scale bars: 10µm. 
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Figure 5. Confirmation of SLP-2-GFP plasmid expression. (a) Representative Western blot analysis showing pSLP-2-GFP 
plasmid expression in differentiated SN56 cells. Whole cell protein lysates were prepared following differentiation induced by 
serum-withdrawal, and transfection by a calcium phosphate method.  Calnexin serves as loading control. (b) Representative 
fluorescence images (600X) showing co-localization (yellow) of SLP-2-GFP and mitochondria in SN56 cells transfected with 
SLP-2-GFP plasmid (pSLP-2GFP, top panels). SN56 cells transfected with GFP plasmid (pEGFP, bottom panels) display a 
diffuse GFP signal.  Hoechst 33258 (blue), a nuclear marker, is shown in the first panel; TOM20 (red), a mitochondrial 
marker, is shown in the second panel; GFP (green), plasmid protein expression marker, is shown in the third panel; and the 
fourth panel shows the first three panels merged together.  
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Figure 9. Percentage (%) apoptosis in GFP-positive SN56 cells following drug treatments. A Live/Dead 
Assay was employed to calculate the percentage of apoptotic cells relative to the total number of cells following 
24 hours treatment with a) 5µM and 50µM MPP+ and b) 40µM CPT in differentiated SN56 cells over-expressing 
GFP plasmid (pEGFP) and SLP-2-GFP plasmid (pSLP-2GFP). Control (Ctrl) cells were untreated. Values 
expressed as mean ± SED for n = 4 per group. Treatment effects *p < 0.05.
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Figure 1 . Induction of SLP-2 has a differential effect on SN56 cell survival in 
response to oxidative stress and DNA damage. A Live/Dead Assay  was employed to 
calculate the percentage of poptotic cells relative to the total number of cells following 
24 hours treatment with a) 5µM and 50µM MPP+ and b) 40µM CPT in diff rentiated 
SN56 cells transfected with EGFP plasmid (pEGFP) and SLP-2-GFP plasmid 
(pSLP-2GFP). Control (Ctrl) cells were untreated. Values expressed as mean ± SE for n = 
4 per group. Treatment effects *p < 0.05.
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Figure 9. Percentage (%) apoptosis in GFP-positive SN56 cells following drug treatments. A Live/Dead 
Assay was employed to calculat  the percentage of apoptotic cells relative to he total number of cells following 
24 hours treatment with a) 5µM and 50µM MPP+ and b) 40µM CPT in differe tiated SN56 cells over-expressing 
GFP plasmid (pEGFP) and SLP-2-GFP plasmi  (pSLP-2GFP). Control (Ctrl) cells were untreated. Values 
expressed as mean ± SED for n = 4 per group. Treatment effects *p < 0.05.
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Figure 17. Induction of SLP-2 is associated with increased OXPHOS Complex I 
protein levels in SN56 cells. Representative Western blot (a) and densitometry  (b-f) 
analysis of protein levels for Complex I (subunit NDU S3), Complex II (subunit  30kDa), 
Co plex III (subunit Core 2), Complex IV (subunit I), and Complex V (subunit alpha) of 
the electron transport chain in differentiated SN56 cells expressing either GFP plasmid 
(pEGFP) of SLP-3-GFP plasmid (pSLP-2-GFP) DNA. Whole cell protein lysates were 
prepared following successful transfection of differentiated SN56 cells. Densitometry 
values are normalized to the loading control, Calnexin.  Values are expressed as mean ± 
SE for n= 3, *p< 0.05.
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Chapter 4: Discussion
Mitochondria are central organelles for a number of critical cellular functions.  Due to a 
number of high-energy demanding neuronal processes, neurons rely heavily on 
mitochondrial function and proper mitochondrial dynamics to maintain proper cellular 
function and homeostasis.  Studies focused on isolated mitochondria and dissociated cell 
cultures have provided insight to the function of this organelle, and have highlighted a 
number of integral proteins involved in the stabilization and proper organization of 
mitochondrial components.  SLP-2 has been shown to be closely linked with 
mitochondrial dynamics, most notably the stress-response, thereby implicating a role for 
this protein in mitochondrial biogenesis, energy production, and programmed cell death.
4.1   Establishment of a model to study the effects of SLP-2 deletion and 
        SLP-2 up-regulation
A systemic deletion of SLP-2 has been shown to result in embryonic lethality 
(Mitsopoulos et al., 2012).  In an effort to characterize SLP-2 deficiency in neurons, we 
employed a conditional knockout mouse expressing Cre recombinase under the control of 
the brain factor 1 promoter.  We have shown that this model results in successful 
forebrain-specific deletion of the SLP-2 gene as it develops in the mouse embryo, from 
which we were able to obtain SLP-2 deficient E14.5-15.5 primary cortical neurons.  
Additionally, C57BL/6 mouse embryos carrying one wild-type SLP-2 allele (SLP-2wt) 
and one flanked SLP-2 allele (SLP-2lox), express a comparable amount of SLP-2 protein 
relative to wild-type C57BL/6 mouse embryos and therefore serve as a suitable model for 
wild-type controls in our experiments.
In an effort to characterize the effects of SLP-2 up-regulation in neurons, we enforced the 
expression of SLP-2-GFP plasmid DNA in the SN56 neuronal cell line.  In agreement 
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with previous studies conducted in a number of non-neuronal cell lines (Wang et al., 
2009; Hajek et al., 2007; Da Cruz et al., 2008, Christie et al., 2012) we have shown that 
SLP-2 co-localizes with the mitochondrial marker TOM20, in the neuronal cell type.
4.2    Conditional SLP-2 knockout mice are similar to wild-type mice: Brain 
         morphology, neuron viability and neuritic outgrowth
Forebrain-specific SLP-2 knockout mice survive to adulthood (P70+), and display no 
significant gross morphological alterations to the brain, when compared to wild-type 
(SLP-2lox/wt) mouse brains.  At 10 weeks of age, forebrains of SLP-2 knockout mice 
appear to have a normal gross neuroanatomy that is devoid of neurodegeneration, and 
Nissl staining of coronal brain sections through the cortex reveal cell density and layering 
that is similar to wild-type forebrain sections.  Although our studies on forebrain-specific 
SLP-2 knockout mouse brains indicate no significant morphological or neuroanatomical 
abnormalities, further microscopic analyses, including immunohistochemical 
characterization of neuronal morphology, perhaps additionally at various stages of 
development, would be useful to rule out potential alterations to other areas or cellular 
components of the brain.  Furthermore, behavioral experiments with adult mice would be 
useful for assessing overall neurotransmission and brain functionality in an effort to 
determine, for example, whether learning, locomotion, sensory capabilities, or drug 
responses are altered as a result of a forebrain-specific SLP-2 deletion.  SLP-2 knockout 
and wild-type adult brains could also be used for further study of anatomical, 
biochemical, and degenerative changes related to lesions associated with stroke, epilepsy, 
or major progressive neurodegenerative diseases such as PD, HD or AD.
In addition, we have shown that in vitro, SLP-2 knockout neurons survive under normal 
culture conditions at levels comparable to wild-type primary cortical neurons.  Moreover, 
we have shown that SLP-2 knockout neurons are MAP2 positive, thereby demonstrating 
dendritic development.  Additional studies on cytoskeletal organization, neuritic 
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branching, branch length, and complexity of neuronal dendritic arbors would be 
necessary to further characterize the functionality of SLP-2 knockout neurons.
4.3   SLP-2 contributes to stabilization of mitochondrial respiratory chain
        proteins
In this study we have shown that SLP-2 is required to stabilize normal levels of a number 
of protein subunits of mitochondrial respiratory complexes.  This is consistent with 
previous studies in HeLa cells, employing short hairpin RNA (shRNA) (Da Cruz et al., 
2008), and  KYSE 150 cells  (an ESCC cell line), employing small interfering RNA 
(siRNA) (Wang et al., 2009), that have demonstrated a decrease in protein levels of 
subunits from Complexes I and IV of the respiratory chain as a result of SLP-2 depletion.  
Similarly, studies in SLP-2 deficient T lymphocytes (T-cells) (Christie et al., 2012) have 
demonstrated decreased protein levels of multiple subunits of Complex I, as well as 
decreased activity at complexes I , II and III of the mitochondrial respiratory chain 
(Christie et al., 2012).  
Alterations to the ETC in T-cells have been associated with impaired 
compartmentalization of cardiolipin, an important IMM protein involved in promoting 
optimal mitochondrial function through the maintenance of membrane potential, fluidity, 
and osmotic stability (Christie et al., 2012).  Cardiolipin is essential for the structural and 
functional stabilization of several mitochondrial respiratory chain complexes, and 
contributes to the regulation of cyt c (Ott et al., 2002; Tuominen et al., 2002; Schlame et 
al., 2005).  Cardiolipin has also been shown to play a critical role in the assembly of ETC 
supercomplexes, as well as mitochondrial biogenesis (Robinson et al., 1993; Schlame et 
al., 2000; Chico and Sparagna, 2006).  
Here we show a significant decrease in protein levels of subunits from all five complexes 
of the respiratory chain [Complex I (subunit NDUFS3), Complex II (subunit 30kDa), 
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Complex III (subunit Core 2), Complex IV (subunit I), and Complex V (subunit alpha)] 
in SLP-2 deficient primary cortical neurons.  This suggests that SLP-2 also contributes to 
the maintenance of mitochondrial membrane potential in neurons, is involved in 
mitochondrial biogenesis, and could perhaps serve a larger role in OXPHOS maintenance 
in neurons than in other cell types, given that we are the first to report a link between 
SLP-2 deficiency and changes in protein levels of subunits from complexes II, III, and V.
In support of this, we have found that in SN56 cells over-expressing SLP-2 there is also a 
significant increase in the level of Complex I (NDUFS3) protein levels.  Additionally, 
although there was no significant difference seen in the protein levels of subunits from 
Complexes II-V, the levels of these proteins do appear to be elevated in SN56 cells over-
expressing SLP-2, relative to control.    
Recent structural and functional evidence has suggested that mitochondrial complexes 
associate with one another to form supramolecular structures, known as supercomplexes, 
in order to carry out their roles as “respirasomes” (Acin-Perez 2008).  These 
supercomplexes seem to offer structural and functional benefits to the OXPHOS system 
by stabilizing and helping to prevent degradation of RC complexes.  This appears to 
improve substrate channeling and electron transport efficiency, and contributes to reduced 
levels of mitochondrial electron and proton leakage (Moran et al., 2012; Koopman et al., 
2010; Lenaz et al., 2010; Wittig et al., 2009).   
Due to the structural interdependence among RC complexes however, structural changes 
or defects affecting one particular complex may have a significant effect on the stability 
of others.  As a result, genetic deficiency of a single complex can result in multiple RC 
enzyme deficiencies (Acin-Perez et al., 2004; Li et al., 2007; Schagger et al., 2001)
Complexes I/III have been shown to form the most abundant and stable supercomplexes, 
particularly in mouse liver mitochondria were the majority of Complexes I and III are 
found in supercomplex form.  Additionally, associations of Complexes III/IV, I/III/IV, II/
III/IV and I/II/III/IV have also been observed, however Complexes II and IV display a 
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larger unassociated fraction than the other respiratory complexes.  Some supercomplexes 
additionally include CoQ and cyt c, and retain the ability to transfer electrons from 
NADH or Complex II to oxygen, thereby indicating a functional role for these 
respirasomes (Schagger and Pfeiffer, 2001; Schagger, 2001; Cruciat et al., 2000; Acin-
Perez et al., 2008).
Our results indicate that SLP-2 depletion in neurons is closely linked with decreased 
respiratory complex protein levels, which thereby indicates a decline in supercomplex 
formation and density.  It is well documented that decreased expression of mitochondrial 
complexes is associated with a decline in mitochondrial respiration, ATP synthesis, and 
mitochondrial membrane potential as well as increased free-radical production most 
likely due to electron leakage.  Given that neurons necessitate such a high amount of 
energy, and are so heavily dependent on functional mitochondrial dynamics and energy 
metabolism, such perturbations to mitochondrial function can have extremely detrimental 
effects.  This is further supported by the prevalence of mitochondrial dysfunction as the 
basis for a number of neurodegenerative disorders (Section 1.1).  Taken together, this 
evidence suggests that through its role in stabilizing mitochondrial respiratory complexes, 
SLP-2 may thereby contribute to maintenance of proper mitochondrial functions and 
bioenergetics, and potentially serve an overall neuroprotective role.
4.4   SLP-2 contributes to maintenance of mitochondrial membrane potential
Our results demonstrate that SLP-2 knockout neuronal cultures display a significantly 
reduced MtrkR fluorescence signal relative to wild-type neuronal cultures.  Given that the 
uptake and accumulation of MtrkR is dependent on mitochondrial membrane potential, a 
decline in the level of MtrkR fluorescence could  indicate not only a decrease in 
mitochondrial mass and density, but also signal to a decline in mitochondrial membrane 
potential.  The level of expression of outer mitochondrial membrane protein TOM20, 
however, is considered a reliable indicator of mitochondrial mass.  When we examined 
the level of membrane potential-independent TOM20 expression in these cells, we were 
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able to conclude that the mitochondrial mass in SLP-2 knockout neuronal cultures is not 
significantly different from that observed in wild-type cultures.  This suggests that the 
decrease in MtkR fluorescence signal observed in SLP-2 knockout cultures is likely due 
to a decline in mitochondrial membrane potential, and correlates with our data regarding 
SLP-2 depletion-associated decreased ETC Complex protein levels.   
Maintenance of the mitochondrial membrane potential is central to the control of calcium 
accumulation within the mitochondrial matrix, mitochondrial respiration and ATP 
synthesis (Ward et al., 2007; Nichols and Budd 2000).  Although establishing the 
mitochondrial membrane potential involves ion transport and therefore requires energy 
expenditure, once this potential is established it is further used to transport additional ions 
and metabolites and drive ATP synthesis.   Neurons are highly metabolic cells that rely 
critically on the energy produced by OXPHOS, as they require large amounts of ATP for 
maintenance of membrane excitability in order to carry out neurotransmission and 
plasticity (Kann and Kovacs, 2007; Billups and Forsythe, 2002).  Taken together, this 
suggests that SLP-2 also contributes to neuronal signaling through stabilizing 
mitochondrial respiratory proteins and maintaining the mitochondrial membrane 
potential.
Additionally, studies in MEFs (Tondera et al., 2009) have shown that active oxidative 
phosphorylation is required for SIMH to occur, thereby revealing that disrupting the 
mitochondrial membrane potential prevents SIMH.  A decline in mitochondrial 
membrane potential in SLP-2 knockout neurons, and a resultant inability to undergo 
protective SIMH, may therefore contribute to increased sensitivity to a number of cell 
stressors in this genotype. 
Mitotracker Green FM (MtkG) is a green-fluorescent dye that localizes to mitochondria, 
in live cells, in a membrane potential-independent manner.  Although our experiments 
with MtkR and TOM20 indicate that a decline in mitochondrial membrane potential in 
SLP-2 knockout neurons is likely, repeating Flow Cytometry and FACS analysis 
experiments with a probe such as MtkG would be a useful method to confirm our results.
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4.5    SLP-2 is up-regulated and associated with a number of sub-cellular
         changes in neurons following stressful stimuli
In this study, we have shown that SLP-2 is up-regulated in primary cortical neurons under 
conditions of direct mitochondrial inhibition and stress, as it is induced by treatment with 
MPP+.  Although this is consistent with previous studies in HeLa cells (Da Cruz et al., 
2009), we have also found that contrary to HeLa cells, in primary cortical neurons, this 
increase in SLP-2 expression was also seen following treatments with the DNA damaging 
agent, CPT.  This could indicate that in neurons, SLP-2 may play a more broad-spectrum 
role in cellular stress-responses.   
4.5.1   Increased mitochondrial mass
When primary cortical neurons are subjected to stressful stimuli that result in increased 
SLP-2 expression, we also see a concomitant increase in mitochondrial mass as indicated 
by increased expression of mitochondrial protein marker TOM20.  This is consistent with 
studies conducted in T-cells which demonstrated an increase in the mass of metabolically 
active mitochondria following up-regulation of SLP-2 (Christie et al., 2011).  Studies in 
MEFs (Tondera et al., 2009) have indicated that SLP-2 is required for SIMH to occur in 
response to a number of selective stresses.  The apparent increase in mitochondrial mass 
following stress treatments in our experiments, however, is also observed in SLP-2 
knockout neuronal cell cultures, and not significantly different from what is observed in 
wild-type neuronal cell cultures.  This suggests that SLP-2 is therefore, not absolutely 
required for the induction of mitochondrial biogenesis that results in response to stress, in 
neurons.
4.5.2   Differential PGC-1α expression
The expression of a key transcriptional co-activator and regulator of mitochondrial 
biogenesis, PGC-1α, is also up-regulated following CPT treatment, but not following 
MPP+ treatment in neuronal cultures.  This up-regulation is also significantly greater in 
SLP-2 knockout neurons, which are also more sensitive, relative to wild-type neurons, to 
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the effects of CPT.  Interestingly, these findings are not consistent with experiments 
conducted in T lymphocytes (Christie et al., 2011) that show that SLP-2 over-expressing 
cells display increased PGC-1α expression levels, thereby suggesting that there may be a 
differential link, between SLP-2 expression levels and other mitochondrially targeted 
proteins such as PGC-1α, in neurons. 
PGC-1α is known to play a prominent role in controlling the expression of genes 
involved in the mitochondrial respiratory chain (Schreiber et al., 2004; Wu et al., 1999), 
as well as in promoting the expression of critical ROS-detoxifying enzymes (St-Pierre et 
al., 2006). Studies conducted in a colorectal tumor cell line (Srivastana et al., 2007) have 
indicated that PGC-1α up-regulation is associated with OXPHOS rescue, through 
stimulation of mitochondrial respiration and expression of several OXPHOS genes, in 
OXPHOS deficient cells.   The increase in PGC-1α expression in response to CPT 
treatment in SLP-2 knockout neurons may therefore represent a cellular effort to improve 
mitochondrial function and protect against the effects of CPT.  This could explain the 
increase in PGC-1α expression in SLP-2 knockout neurons relative to wild-type, based on 
the decreased levels of OXPHOS proteins we have reported as part of the SLP-2 
knockout neuronal phenotype.  
Based on these findings, it would be interesting to look at the relative protein levels of 
OXPHOS proteins following MPP+ and CPT treatments, to determine whether the 
induction of PGC-1α in response to stress treatments is similarly associated with 
increased levels of OXPHOS proteins in neurons.
Despite an observed resultant increase in mitochondrial mass, PGC-1α up-regulation in 
neurons, as well as in cardiac and muscle tissue, has also been shown to result in a 
significant decline in both respiratory reserve capacity and mitochondrial membrane 
potential (Russel et al., 2004; Ciron et al., 2011).  Additionally, it has been linked with 
alterations in axonal trafficking and mitochondrial movement in dopaminergic neurons, 
which can ultimately result in axonal degeneration and cell death (Ciron et al., 2011).  
Taken together, these findings may explain the increased sensitivity of SLP-2 knockout 
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neurons to the effects of CPT as perhaps a result of, or contributing effect of, PGC-1α up-
regulation.  Additionally, the lack of PGC-1α up-regulation in response to MPP+ 
treatment may indicate a form or mechanism of cellular defense in SLP-2 knockout 
neurons in an effort to prohibit or circumvent the potential negative effects of PGC-1α 
up-regulation.  
Furthermore, PGC-1α is considered one of the major controllers of mitochondrial 
biogenesis and mtDNA transcription.  The action of PGC-1α includes downstream 
activation of other regulators of mitochondrial biogenesis such as Nuclear respiratory 
factors 1 (NRF1) and 2 (NRF2), and mitochondrial transcription factor A (Tfam).  Recent 
studies in mice have shown that observed increases in both NRF1 and Tfam, as a result of 
exercise, can occur independently of PGC-1α activation or ROS, thereby indicating that 
these regulatory proteins may be up-regulated by other mechanisms (Koltai et al., 2012).  
Conversely, upstream regulators of PGC-1α such as the calcineurin-A- and CaMK-
mediated, or protein kinase B/Akt-mediated pathways can, respectively, activate or 
suppress PGC-1α transcription (Czubryt et al., 2003; Handschin et al., 2003; Scheffer et 
al., 2003; Herzig et al., 2001).
Our results indicate that in both wild-type and SLP-2 knockout neurons, PGC-1α does 
not contribute to the increase in mitochondrial mass observed following treatment with 
MPP+.  Additional studies aimed at examining the expression levels of other co-
activators or inducers of mitochondrial biogenesis (such as NRF1/2 and Tfam) or 
upstream regulators of PGC-1α expression (such as transcription factors involved in the 
calcineurin A-, CaMK-, or protein kinase B/Akt-mediated pathways), under conditions or 
following treatments similar to those employed in our experiments, could provide further 
insight to the mechanisms of mitochondrial biogenesis in neurons with different 
expression levels of SLP-2 and in response to drugs with different targets.   
4.5.3   Differential survival response to stress induced by drug treatments
In this study we have shown that SLP-2 knockout neurons are significantly more prone to 
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cell death resulting from the detrimental effects of DNA damage (CPT).  These results are 
consistent with previous studies, in SLP-2 depleted MEFs (by shRNA), that have 
indicated that mitochondria may undergo protective SIMH in response to a number of 
apoptosis-inducing cell stressors, such as UV irradiation or Actinomycin D (Tondera et 
al., 2009).  This suggests that a lack of SIMH, as a result of SLP-2 depletion, could 
contribute to the increased sensitivity of SLP-2 knockout neurons to the effects of CPT.  
The treatments used in the experiments examining SIMH (Tondera et al., 2009) however, 
examined the effects of a number of DNA damaging agents and inhibitors of protein and 
RNA synthesis, like CPT, but did not examine the effects of direct mitochondrial 
stressors, such as MPP+ or 3-NP, which were employed in our experiments.
Interestingly, we show that SLP-2 knockout neurons are more resistant to the effects of 
MPP+ and 3-NP.  This may suggest, that under these conditions, depletion of SLP-2 
confers on cells a specific resistance to the stress resulting from direct mitochondrial 
inhibition.  Furthermore, our results have shown that SLP-2 knockout neurons display 
significantly decreased protein levels of subunits of all five complexes involved in 
OXPHOS.  A decline in OXPHOS results in diminished ATP production, reduction in the 
activity of ATP synthase in maintaining the mitochondrial membrane potential, and 
thereby results in decreased ROS production and decreased apoptotic sensitivity (Wu et 
al., 2006).  Up-regulation of SLP-2 has been closely linked with a number of metastatic 
cancers, and associated with increased tumor cell motility, proliferation, and 
chemotherapeutic resistance (Wang et al., 2009).  
In line with our experiments conducted in primary cortical neurons, we found that 
relative to control SN56 cells, SN56 cells that over-express SLP-2 are more sensitive to 
the effects of MPP+ and more resistant to the effects of CPT.  This suggests that up-
regulating SLP-2 in the neuronal cell type results in capacity to withstand cellular stress 
that results from DNA damage, which could be explained due to perhaps a resultant 
increase in mitochondrial biogenesis and function, as is seen in the SIMH response that is 
shown to require SLP-2 (Tondera et al., 2009).  The increased sensitivity of SN56 cells 
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over-expressing SLP-2, however,  could be explained by an increase in OXPHOS protein 
levels, with a potential increase in ROS production, thereby rendering cells more 
apoptosis-prone.   Figures 18 and 19 provide a schematic overview summarizing our 
main findings from survival response experiments employing MPP+, 3-NP and CPT. 
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Figure 18. The level of SLP-2 expression alters the level of mitochondrial ROS 
production induced by mitochondrial stressors MPP+ and 3-NP in neurons.  Relative 
to wild-type neurons (panel II), SLP-2-depleted neurons (panel I, SLP-2 knockout 
neurons) display decreased levels of mitochondrial RC complex subunits, while SLP-2 
over-expressing SN56 cells (panel III) display increased levels of mitochondrial RC 
complex subunits.  As a result, SLP-2 knockout neurons (panel I) treated with inhibitors 
of mitochondrial respiration (either MPP+ targeting complex I, or 3-NP targeting 
complex II) display decreased production of ROS (HO*, O2-, and H2O2) by  OXPHOS, 
relative to wild-type (bottom panels I and II). Conversely, SLP-2 over-expressing neurons 
(panel III) treated with MPP+ (3-NP data not available) may lead to enhanced ROS 
production (bottom panel III) and oxidative stress due to the increased levels of 
OXPHOS proteins.  As a result  of altered ROS production, SLP-2 knockout neurons 
(panel I) are more resistant to the effects of mitochondrial stress (induced by MPP+ and 
3-NP) while SLP-2 over-expressing neurons (panel III) are more sensitive to the same 
effects (induced by MPP+), relative to wild-type (panel II).
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Figure 18. The level of SLP-2 expression alters the level of mitochondrial ROS production induced by mitochondrial stressors MPP+ and 3-NP. In this study we have shown that there is 
an inverse relationship between the level of SLP-2 expression and levels of mitochondrial respiratory chain proteins in neuronal mitochondria.  Relative to wild-type neurons (panel II), decreased 
SLP-2 expression (panel I, SLP-2 knockout neurons) correlates with decreased levels of mitochondrial RC complex subunits, while increased SLP-2 expression (panel III, SLP-2 over-expressing 
SN56 cells) correlates with increased levels of mitochondrial RC complex subunits.  As a result, SLP-2 knockout neurons (panel I) treated with inhibitors of mitochondrial respiration (either MPP
+ ta geting complex I or 3-NP targeting complex II) display decreased production of ROS (HO*, O2-, and H2O ) by OXPHOS, relative to wild type. Conversely, SLP-2 over-expressing neurons 
(panel III) treated with the same mitochondrial inhibitors may lead to enhanced ROS production and oxidative stress due to the increased levels of OXPHOS proteins.  As a result, SLP-2 knockout 
neurons are more resistant to the effects of mitochondrial stress (induced by MPP+ and 3-NP) while SLP-2 over-expressing neurons are more sensitive to the same effects.
1 II III
Figure 19. The level of SLP-2 expression alters mitochondrial dynamics in response 
to DNA damage induced by CPT in neurons.  In our study we have shown that  the 
level of SLP-2 expression does not have an effect on mitochondrial mass under normal 
cell culture conditions (top panels I-III).  When DNA damage is induced by treatment 
with CPT, mitochondria of SLP-2 knockout neurons (bottom panel I) are unable to 
undergo SIMH (due to the absence of SLP-2), which may  result in increased 
mitochondrial fragmentation in response to the cell stressor, rendering these neurons 
more susceptible to cell death, relative to wild-type (panel II) (able to undergo SIMH due 
to the presence of SLP-2).  Conversely, mitochondria of SLP-2 over-expressing neurons 
(panel III), may  undergo a hyperfusion (SIMH) response (bottom panel III) that is even 
greater than that which is observed in wild-type neurons (panel II) as a result  of greater 
stabilization of critical SIMH proteins (such as L-OPA1) due to increased availability of 
SLP-2.  As a result, due to perhaps the protective effects of SIMH, SLP-2 over-expressing 
neurons are more resistant to the effects of CPT, relative to wild-type.   
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Figure 19. The level of SLP-2 expression alters mitochondrial dynamics in response to DNA damage induced by CPT.  In our study we have shown that the level of SLP-2 expression does 
not have an effect on mitochondrial mass under normal cell culture conditions (top of panels I-III).  When DNA damage is induced by treatment with CPT, however, mitochondria of SLP-2 
knockout neurons (panel I) are unable to undergo SIMH (due to the absence of SLP-2), which may result in increased mitochondrial fragmentation, rendering these neurons more susceptible to 
cell death, relative to wild-type (panel II).  Conversely, mitochondria of SLP-2 over-expressing neurons (panel III), may undergo a hyperfusion (SIMH) response that is even greater than that 
which is observed in wild-type neurons (panel II) as a result of greater stabilization of critical SIMH proteins (such as L-OPA1) due to increased availability of SLP-2.  As a result, due to the 
protective effects of SIMH, SLP-2 over-expressing neurons are more resistant to the effects of CPT,   
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Additional experiments examining the relative levels of ATP production and ROS 
production in both SLP-2 depleted and SLP-2 over-expressing cells, not only under 
normal culture conditions, but in response to the stress treatments employed in our 
experiments, would help determine whether the differential susceptibility of neurons to 
the induction of apoptosis in our experiments is dependent on the level of mitochondrial 
stability and OXPHOS function.  Additionally, examining mitochondrial network 
organization by immunohistochemistry or Mitotracker fluorescence, both at baseline and 
under stress conditions, may provide further insight to whether or not neurons undergo 
mitochondrial network reorganization or SIMH as a result of differential expression of 
SLP-2, or in response to stressful stimuli.
Further investigation of our findings, by exposing both SLP-2 knockout and wild-type 
primary cortical neurons to alternative mitochondria- and DNA-damaging agents, are 
necessary to  determine whether the effects observed in our experiments are consistent 
depending on drug targets or unique to the treatments that were herein employed.
4.6    Conclusion
In this study, we have for the first time shed light on the role of SLP-2 in mitochondrial 
stress responses, bioenergetics, and apoptosis in the neuronal cell type.  In support of our 
hypothesis, we have shown that SLP-2 plays a role in altering cellular responses and the 
ability of neurons to either withstand or succumb to the effects of various cell stressors, 
depending on their targets.  We have been able to conclude that in neurons, SLP-2 is 
involved in stabilizing a number of mitochondrial respiratory chain proteins, thereby 
contributing to maintenance of mitochondrial membrane potential, and differentially 
altering cellular responses to stress.  Furthermore, although SLP-2 is not required for 
neuronal development, differential expression of this protein in neurons appears to be 
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closely linked with both apoptosis induction and suppression, depending on the insult to 
the cell.
This knowledge of the SLP-2 knockout neuronal phenotype will improve our 
understanding of neuronal stress responses and proteins necessary for development. 
Studies aimed at characterizing cellular responses to conditions of stress often look at 
changes that influence, or occur as a result of, differential levels of protein expression.  
Identifying and investigating proteins such as SLP-2, that are expressed differentially 
under various stress conditions, may be useful for development of therapeutic strategies 
to target invasive cells in tumors, or to evade the onset or progression of 
neurodegeneration. 
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Appendix A   Conditional SLP-2 Knockout Mouse Breeding Paradigm
Note: SLP-2lox/wt denotes loxP sites flanking SLP-2 on one allele 
(heterozygous); SLP-2lox/lox denotes loxP sites flanking SLP-2 on both alleles 
(homozygous); SLP-2wt/wt/Cre+ denotes a transgenic mouse expressing cre 
recombinase (Cre+) under the control of the BF-1 promoter
E14.5-15.5: embryonic day 14.5-15.5 (calculated based on when male and 
female were paired) 
♂/♀ indicates that genotype not sex-specific - either male or female mouse in 
the breeding-pair could present this genotype, so long as both genotypes 
indicated are present in the pair
PCN: Primary cortical neuron
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Appendix B     Qiagen PCR reagents, cycling conditions, and primers 
for mouse genotyping
Table 3. Qiagen PCR reagents and volumes for SLP-2 primers
Reagent Volume
QIAGEN 10x Buffer 2.5µL
25mM MgCl2 1.75µL
2.5mM dNTPs 2.0µL
5µM SLP-2 1a 2.0µL
5µM SLP-2 1b 2.0µL
5µM SLP-2 1c 2.0µL
Q-Solution 5.0µL
H2O (RNAse/DNAse free) 5.5µL
Taq DNA Polymerase 0.25µL
Total Master Mix 23µL
Sample DNA (~0.5µg/µL) 2µL
Total 25µL
Table 4. PCR Cycling Conditions for SLP-2 Primers
Temperature (℃) Time (minutes) Duration (cycles)
1 94 2:00 x 1
2 94 0:45
x 32
3 55 1:00
4 72 1:00
5 72 4:00
6 4 ∞ x ∞
SLP-2 primers
SLP-2 forward: 5’-ACT TCC ACC CTT CAG TCC AGG TCG-3‘    
SLP-2 reverse: 5’-ACT TGG ATT CTG TGA AAG CAG ACA C-3’ 
SLP-2 deletion: 5’-GGA GTG GAC CAG CTG AAG GAG-3‘
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Table 5. Qiagen PCR reagents and volumes for Cre primers
Reagent Volume
QIAGEN 10x Buffer 2.5µL
25mM MgCl2 2.0µL
2.5mM dNTPs 2.0µL
5µM Cre 2a 2.0µL
5µM Cre 2b 2.0µL
Q-Solution 5.0µL
H2O (RNAse/DNAse free) 7.25µL
Taq DNA Polymerase 0.25µL
Total Master Mix 23µL
Sample DNA (~0.5µg/µL) 2µL
Total 25µL
Table 6. PCR Cycling conditions for Cre primers
Temperature (℃) Time (minutes) Duration (cycles)
1 94 3:00 x 1
2 95 0:45
x 32
3 55 0:45
4 72 1:30
5 72 5:00
6 10 ∞ x ∞
Cre primers
Cre forward: 5’-GGA CAT GTT CAG GGA TCG CCA GGC G-3’  
Cre reverse: 5’-GCA TAA CCA GTG AAA CAG CAT TGC TG-3’
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Appendix C   Qiagen RT-PCR reagents and primers for SLP-2, 
PGC-1α, and S12 genes
Reagent Volume
2x QuantiTect SYBR Green RT-PCR Master Mix 12.5µL
5µM Forward primer 3µL
5µM Reverse primer 3µL
H2O (RNAse/DNAse free) 2.25µL
QuantiTect Fast RT mix 0.25µL
Total Master Mix 21µL
SLP-2 Primers
SLP-2 forward: 5′-GTG AC TCT CGA CAA TGT AAC-3′
SLP-2 reverse: 5′-TGA TCT CAT AAC GGA GGC AG-3′
PGC-1α Primers
PGC-1α forward: 5’-TCA GTC CTC ACT GGT GGA CA-3’
PGC-1α reverse: 5’-TGC TTC GTC GTC AAA AAC AG-3’  
S12 Primers
S12 forward: 5’-GGA AGG CAT AGC TGC TGG-3’
S12 reverse: 5’-CCT CGA TGA CAT CCT TGG-3’
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Appendix D   Representative fluorescence images demonstrating 
apoptotic nuclei as determined by Hoechst 33342 staining
Differentiated SN56 cells were stained with 1µM Hoechst 33342 fluorescent 
dye.  Apoptotic nuclei are distinguished by characteristic condensed, pyknotic 
nuclei (arrows) and a brighter fluorescence emission.  Arrow heads provide 
examples of normal nuclear morphology.  Scale bar: 10µm.
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Differentiated SN56 cells were stained with 1µM Hoechst 33342 fluorescent dye.  Apoptotic nuclei are distinguished 
by characteristic condensed, pyknotic nuclei (arrows) and a brighter fluorescence emission.  Arrow heads provide 
examples of normal nuclear morphology. 
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